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 Approximately 10–15% of first ischemic strokes occur under age 50, with 25% 
occurring in working-age adults (Maaijwee et al., 2014); thus, they have a sub-
stantial social effect, given the patients’ demanding work and family responsi-
bilities. The incidence of young ischemic stroke has greatly increased in recent 
decades, whereas in older age groups, the incidence of ischemic stroke has 
declined (George et al., 2011; Kissela et al., 2012; Ramirez et al., 2016; 
Rosengren et al., 2013; Tibæk et al., 2016). Traditionally, stroke in the young 
has been linked to rare causes and risk factors; however, increasing evidence 
suggests that the prevalence of traditional risk factors in young patients is much 
larger than previously recognized. The rising frequency of vascular risk factors 
and improved detection of stroke with magnetic resonance imaging (MRI) are a 
few possible explanations for the increased incidence of ischemic stroke in 
young adults (Putaala, 2016).  
While stroke mortality is considerably lower among young compared to 
older patients (Fonarow et al., 2010), their risk of dying at young age is still 4–
15 times higher than that of age-matched non-stroke counterparts (Aarnio et al., 
2014; Giang et al., 2013; Marini et al., 1999; Rutten-Jacobs et al., 2013; Waje-
Andreassen et al., 2007). Therefore, identifying the determinants that influence 
both short- and long-term prognoses to plan optimal preventive strategies is 
essential. Having an accurate prognosis allows young patients to make know-
ledgeable decisions about their work, family, and social life. 
Due to the longer expected survival, young stroke patients’ health-related 
quality of life (HRQOL) becomes relevant, as it evaluates patients’ perspectives 
in terms of physical, emotional, social, and other domains. However, data 
regarding long-term HRQOL and its predictors in this specific population are 
limited and need to be updated. 
The most recent population-based stroke registries in Estonia date back to 
1991–1993, 2001–2003 and 2013–2017. They found a higher incidence of 
stroke in young Estonian patients than in Western European countries (Kõrv et 
al., 1996; Kõrv et al., 2021; Vibo et al., 2007). The results showed that Estonian 
men experience stroke 2–7 years and women up to 5 years earlier than their 
Western European counterparts (Kõrv et al., 1996; Vibo et al., 2007). In 
addition, the long-term mortality among stroke patients under age 45 was high 
and remained unchanged between 1991 and 2003 (Vibo et al., 2012). Taking 
this into account, we hypothesized that these findings were primarily a con-
sequence of the early accumulation of stroke risk factors. Therefore, this study 
aimed to examine the etiology and risk factor profiles, update mortality data, 




2. REVIEW OF THE LITERATURE 
2.1. Incidence and Prevalence  
Ischemic stroke in young adults has usually been defined using upper age thres-
hold of 50–55 years. Between 10 and 15% of first ischemic strokes occur in 
people under age 50 (Maaijwee et al., 2014). In European countries, the inci-
dence of ischemic stroke in young adults ranges from 5–35 per 100,000 person-
years (Ekker et al., 2019; Kõrv et al., 2021; Putaala et al., 2009a; Tibæk et al., 
2016), while in sub-Saharan Africa, it is more than 100 per 100,000 person-
years (Walker et al., 2010). In comparison, the general incidence of ischemic 
stroke in Europe is between 83–479 per 100,000 person years (Krishnamurthi et 
al., 2013). The variability in incidence may account for differences in stroke 
definition and subtypes, age cut-offs, case-ascertainment methods, prevalence 
of vascular risk factors, heredity, socio-economic situations, and geographical 
conditions. Previous population-based registries in Estonia dating back to 1991–
1993 and 2001–2003 found a higher incidence of stroke in young adults in 
Estonia compared to studies conducted in Northern and Western Europe. Ac-
cording to these results, Estonian men experience stroke 2–7 years and women 
up to 5 years earlier than their European counterparts (Kõrv et al., 1996; Vibo et 
al., 2007).  
Female predominance is characteristic of ischemic stroke in patients who are 
younger than 30–35 years (Putaala et al., 2009a; Putaala et al., 2012a; Rolfs et 
al., 2013; Spengos & Vemmos, 2010), with an exception being found in Nor-
way where men outnumber women under age 30 years (Naess et al., 2011).  
This pattern of findings can likely be explained by sex-specific risk factors, 
such as pregnancy and puerperium, oral contraceptives, migraine, and some 
autoimmune diseases (e.g., systemic lupus erythematosus, antiphospholipid 
syndrome, Sneddon syndrome; Ekker et al., 2018).  
While there has been an overall decline in stroke incidence in high-income 
countries (Feigin et al., 2009), the incidence of ischemic stroke in young adults 
has been increasing worldwide, and the incidence has increased up to 74% 
(Béjot et al., 2014; Cabral et al., 2017; Ekker et al., 2019; George et al., 2017; 
Kissela et al., 2012; Medin et al., 2004; Tibæk et al., 2016). The causes for this 
rise are likely multifactorial, including improved stroke awareness in the gene-
ral population, the increased accuracy of detection using diffusion-weighted 
MRI, and increased prevalence of modifiable risk factors, such as hypertension, 
diabetes, obesity, and use of illicit drugs (Ekker et al., 2018).  
Given these trends and the declines in mortality (Giang et al., 2013; Koton et 
al., 2014), the prevalence rate of ischemic stroke has increased globally by more 
than 90% in the last two decades, being 176 per 100,000 among adults aged 20–
64 years in 2013, and the incidence of ischemic stroke cases in this age group 




2.2. Risk Factors  
Ischemic stroke risk factors can be categorized as either modifiable or non-
modifiable factors, with modifiable risk factors being further divided into well-
documented and less well-documented (Meschia et al., 2014). The nonmodi-
fiable risk factors are age, low birth weight, race/ethnicity, and genetic factors. 
Since most genetic factors can currently not be treated, they are considered non-
modifiable, although some genetic conditions, such as Fabry disease and sickle 
cell disease, can be treated. Modifiable well-documented risk factors of stroke 
include physical inactivity, dyslipidemia, hypertension, obesity, diabetes, ciga-
rette smoking, atrial fibrillation, and structural cardiac diseases. The list of less 
well-documented risk factors is extensive and continually increasing, including 
factors such as migraine, malignancy, high-risk alcohol consumption, illicit 
drug use, and oral contraceptive use.  
 
 
2.2.1. Modifiable well-documented risk factors 
These, so called traditional vascular risk factors are prevalent in young patients 
with ischemic stroke. According to the largest prospective dataset, the Stroke in 
Young Fabry Patients Study (SIFAP), the most frequent vascular risk factors 
included abdominal obesity (64%; i.e., waist circumference ≥ 94 cm for men 
and ≥ 80 cm for women), current or recent smoking (56%), physical inactivity 
(48%; i.e., walking less than a mile per day), hypertension (47%), and dyslipi-
demia (37%). The prevalence of diabetes, cardiovascular disease, and atrial 
fibrillation was ≤ 10%. Dyslipidemia, smoking, hypertension, cardiovascular 
disease, and diabetes were found to be more frequent in men than women, while 
abdominal obesity occurred more often in women than men. All risk factors, 
except smoking, accumulated over the course of aging in both sexes. Young 
stroke patients rarely have none of these risk factors—within the SIFAP cohort, 
those without risk factors represented only 11.5% of the sample (von Sarnowski 
et al., 2013). A Norwegian study found that the prevalence of hypertension, 
atrial fibrillation, smoking, and diabetes was high, but significantly different 
among patients aged 15–49 years and those over 49 years  (23% vs. 55%, 4% 
vs. 31%, 36% vs. 23%, and 7% vs. 15%, respectively; Nacu et al., 2016).  
In the United States’ inpatient database, a significant increase was observed 
in the prevalence of hypertension, lipid disorders, diabetes, smoking, and obe-
sity in young ischemic stroke patients over a period of eight years, with the pro-
portion of patients having three or more well-documented risk factors doubling 
in both sexes and all age groups (George et al., 2017).  
The association between well-documented risk factors and specifically 
young-onset ischemic stroke was well established in two recent large case-
control studies (Aigner et al., 2017; Kivioja et al., 2018). These studies found 
significant associations for atrial fibrillation (OR = 10.4), cardiovascular disease 
(OR = 8.0), type 1 diabetes (OR = 6.7), physical inactivity (OR = 5.9), type 2 
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diabetes (OR = 2.3), low high-density lipoprotein (OR = 1.8), current smoking 
(ORs = 1.5–1.8), hypertension (ORs = 1.4–2.3), and obesity (OR = 1.2), while 
no association was found for hyperlipidemia (Aigner et al., 2017; Kivioja et al., 
2018). Age-, sex-, and etiology-specific subgroups were reported to have diffe-
rent risk profiles; however, current smoking and type 1 diabetes were strongly 
associated across all subgroups (Kivioja et al., 2018).  
Population attributable risk (PAR) characterizes how a risk factor contri-
butes to the burden of stroke. In a German study, the highest PARs were found 
for physical inactivity (60%), hypertension (25%), heavy alcohol consumption 
(17%), and smoking (15%; Aigner  et al., 2017). The combined PAR of these 
four factors accounted for 78% of the risk, and the behavioral factors only (i.e., 
physical inactivity, alcohol consumption, and smoking) encompassed 71% 
(Aigner et al., 2017). Additionally, the Finnish study identified the PARs for 
several medical risk factors, including low high-density lipoprotein (7%), 
cardiovascular disease (4%), type 1 diabetes (4%), type 2 diabetes (3%), and 
atrial fibrillation (2%; Kivioja et al., 2018).  
 
 
2.2.2. Less well-documented risk factors 
The evidence for less well-documented risk factors comes from research in-
volving smaller cohorts, and these findings have shown some variation across 
studies. These risk factors are prevalent in the young general population, and in 
order to lead to ischemic stroke, they often need to interact with additional 
conditions.  
Migraine. Migraine with aura has the most well-established link with 
ischemic stroke among these less well-documented risk factors. Research indi-
cates that it elevates stroke risk by approximately two-fold when compared to 
those who do not experience migraine (Etminan et al., 2005; Hu et al., 2017; 
Schürks et al., 2009; Spector et al., 2010). Regarding migraine without aura, 
results have been inconsistent, and the majority have not identified a significant 
relationship with ischemic stroke (Adelborg et al., 2018; Etminan et al., 2005; 
Hu et al., 2017; Schürks et al., 2009; Spector et al., 2010). Migraine appears to 
have an additive effect on risk when it is present in individuals who smoke and 
use oral contraception (Schürks et al., 2009). A Danish population-based study 
reported an eightfold risk of ischemic stroke during the first year after migraine 
diagnosis, which decreased thereafter (Adelborg et al., 2018). A stronger 
association has also been found for women, those under age 45, and for active 
migraine (i.e migraine headaches in the prior year; Kurth et al., 2006; Schürks 
et al., 2009).  
Malignancy. Large studies have demonstrated an increased risk for ischemic 
stroke in patients with tumors. A study conducted in the UK reported a 50% 
increase in morbidity with higher risks being found in individuals aged 15–19 
years and with central nervous system tumors, neck and head tumors, leukemia, 
and Hodgkin lymphoma (Bright et al., 2017).   
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Among a sample of young Finnish stroke patients, 4% had either a pre-
stroke or post-stroke cancer diagnosis. Those with cancer had higher 10-year 
mortality, which was associated with active cancer at index stroke, and mela-
noma and lung cancer (Aarnio et al., 2015). Pathophysiologically, the link 
between malignancy and stroke could be mediated through coagulation dis-
orders, infections, or direct vessel compression, as well as the effects of chemo-, 
radio-, or surgical therapy (Dardiotis et al., 2019).  
High-risk alcohol consumption. In the SIFAP Study, high alcohol con-
sumption was reported by 33% of patients (von Sarnowski et al., 2013). The 
risk of stroke has been shown to increase by two in episodic and by 15 in 
chronic young alcohol users compared with non-users (Aigner et al., 2017; You 
et al., 1997). Alcohol use can trigger stroke through cardiac arrhythmias, 
coagulation disorders, and trauma, which may lead to cervical artery dissection 
(Tatlisumak & Thomassen, 2018). 
Illicit drugs. Approximately 5% of the general population between 15–64 
years of age use illicit drugs annually. The illicit drugs most frequently related to 
ischemic stroke are psychomotor stimulants, especially cocaine and amphetamine 
(Fonseca et al., 2013). The mechanism of stroke depends on the method of action 
and administration of the drug. Intravenous administration often leads to stroke 
through a thromboembolic mechanism and the inhalation of methamphetamine 
has a higher prevalence of ischemic stroke than hemorrhagic stroke (Lappin et al., 
2017). The mechanism of stroke is best understood for cocaine and amphetamine, 
which can induce vasospasm, cardiomyopathy, vasculitis, and premature athero-
sclerosis. For several drugs, the mechanism of stroke remains unclear (Fonseca et 
al., 2013).  
Oral contraceptives. The relative risk of ischemic stroke in combined oral 
contraceptive users compared with non-users was 1.7. The risk increases for 
those who are taking high estrogen doses, while it is not different between 
progestogen generations (Roach et al., 2015).   
Pregnancy. Risk of ischemic stroke related to pregnancy is highest during 
the peripartum and postpartum periods. The absolute incidence rate is low (12.2 
of 100,000 pregnancies; Swartz et al., 2017), but has increased over the past 
decades (Karjalainen et al., 2021). The mechanisms by which pregnancy-related 
ischemic stroke might occur include hypercoagulability, peripartum cardiomyo-
pathy, hypertensive disorders, postpartum angiopathy, amniotic fluid embolism, 
and choriocarcinoma (van Alebeek et al., 2018). 
Patent foramen ovale (PFO). PFO is present in 29–73% of young patients 
with cryptogenic stroke, while its prevalence in the general population is around 
25% (Alsheikh-Ali et al., 2009). The relative risk of having PFO in cryptogenic 
stroke in patients <55 years of age is 5.1, compared with ischemic stroke with a 
known cause (Alsheikh-Ali et al., 2009). The Risk of Paradoxical Embolism 
Study (RoPE) aimed to create a prediction score that could estimate the 
likelihood of a causal (vs. incidental) relationship between a current stroke and 
PFO. The factors that have been found to increase the probability of this causal 
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relationship include younger age, absence of vascular risk factors, and cortical 
infarction on imaging (Appendix A; Kent et al., 2013).  
Acute and chronic infections. Both acute and chronic infections are 
associated with an increased risk of ischemic stroke. Young individuals seem to 
have a higher relative risk of infection-related stroke than their older counter-
parts (Grau et al., 2010). The strongest association with stroke in young patients 
has been established for infections with Chlamydia pneumonia, HIV (human 
immunodeficiency virus), and periodontal disease (Benjamin et al., 2012; Grau 
et al., 2010; Lin et al., 2019). Due to COVID-19 the rate of large vessel stroke 
among young individuals without traditional risk factors increased seven-fold 
from 2019 to 2020 (Fifi & Mocco, 2020; Oxley et al., 2020). A study conducted 
in Finland found that 10.3% of young stroke patients had an infection, most 
frequently in the upper respiratory tract, prior to their stroke, and they had 
worse functional outcome at three months compared with those without an 
infection, with an OR of 2.86 (Heikinheimo et al., 2013). Various mechanisms 
could explain the occurrence of infection-related stroke, such as activation of 
procoagulant pathways, endothelial dysfunction, promotion of atherosclerosis, 
and direct damage to the tunica media (Grau et al., 2010).    
Antiphospholipid antibodies. Ischemic stroke is a defining event for anti-
phospholipid syndrome when accompanied by the persistent presence of anti-
phospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies, 
or β-2 glycoprotein I. A systematic review reported that the frequency of anti-
phospholipid antibodies in young stroke patients was 17%, and their presence 
resulted in a five-fold higher risk of stroke compared with antibody-negative 
controls (Sciascia et al., 2015). A Dutch study of women under 50 years of age 
demonstrated that ischemic stroke in antiphospholipid syndrome was predo-
minantly associated with the presence of lupus anticoagulant, and the risk 
further increased when accompanied by the use of oral contraceptives or 
smoking (Urbanus et al., 2009).  
Genetic risk factors. Genetic thrombophilias are strongly associated with 
venous thrombosis, but their role in arterial thrombosis remains controversial. A 
recent meta-analysis concluded that factor V Leiden gene polymorphism, the 
most prevalent hereditary hypercoagulability disorder, moderately increased the 
risk of ischemic stroke in those 40 years and younger, but not in those who are 
older than age 40 years (Alhazzani et al., 2018). Likewise, in another meta-
analysis, the association of prothrombin G20210A mutation with ischemic 
stroke was rather modest (OR = 1.4) and significant only in adults under age 55 
(Jiang et al., 2014).  
Other factors. Long working hours, shift work, air pollution, and psycho-
logical stress have recently been described as potential risk factors for ischemic 
stroke among young adults, but have been less studied (Putaala, 2016).  
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2.3 Classification  
In clinical and research settings, ischemic stroke is generally classified using the 
Trial of Org 10172 in Acute Stroke Treatment Classification (TOAST) classi-
fication, which differentiates between five etiological subtypes: large artery 
atherosclerosis (LAA), cardioembolism (CE), small-artery occlusion (SAO), 
stroke of other determined etiology (ODE), and stroke of undetermined etiology 
(UND). The last group includes three distinct subgroups: 1) no obvious cause 
despite extensive diagnostic evaluation (i.e., cryptogenic stroke); 2) two or 
more concurrent causes; and 3) no cause due to incomplete diagnostic evalua-
tion (Appendix B; Adams et al., 1993). While the definitions of the first four 
groups are sufficiently accurate, the undetermined group of TOAST might be 
too unspecific for classifying young-onset stroke. The proportion of patients in 
that group includes up to 50% of patients and is even higher among cohorts of 
very young adults (Putaala et al., 2017). To minimize the size of the UND 
etiology group, Ay et al. (2007) developed an online classification algorithm 
(Causative Classification System for Ischemic Stroke; Ay et al., 2007). It has 
also been suggested that the UND etiology group should include only pure 
cryptogenic cases, and separate categories should be allocated for incomplete 
work-up, two or more competing causes, and paradoxical embolism, including 
PFO (Tatlisumak & Thomassen, 2018). The atherosclerosis, small vessel 
disease, cardiac source, other cause classification (ASCO), where each etiolo-
gical group is given a score according to its likelihood of causing the ischemic 
event (Amarenco et al., 2009), is yet another way to classify ischemic stroke. 
Unfortunately, reclassification of the patients in the SIFAP Study with this 
scoring method further decreased the proportion of patients with obvious causes 
(Wolf et al., 2015), suggesting that ASCO scoring will be more widely used in 




2.4.1. Large artery atherosclerosis 
Atherosclerosis is a chronic inflammatory disease that starts from the intima 
and subsequently affects the media and adventitia of large- and medium-sized 
arteries. It begins in infancy and its course of development depends on vascular 
risk factors, including genetic predisposition (Tatlisumak & Thomassen, 2018). 
Various mechanisms can cause stroke in atherosclerosis. Stroke may arise from 
atheroembolism, thromboembolism from the atherosclerotic plaque surface, or 
vessel occlusion due to plaque rupture and thrombosis (Tatlisumak & Thomas-
sen, 2018). In the TOAST classification, atherosclerosis is considered causative 
of stroke if the stenosis of extra- or intracranial arteries by a plaque is >50% 
(Adams et al., 1993). However, this correlation is not always valid, since some-
times even <50% stenosis may cause a cerebrovascular event (Tatlisumak & 
Thomassen, 2018). Methods of arterial imaging include conventional digital 
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subtraction angiography, computed tomography angiography, magnetic reso-
nance angiography, and ultrasonography. Of these, ultrasonography has the 
least side effects, yet is the most operator-dependant (Kittner & Singhal, 2013). 
The majority of studies have reported stroke due to large artery atherosclerosis 
in 8–19% of young patients depending on the upper age limit of the study 
population (Barlas et al., 2013; Putaala et al., 2009a; Rolfs et al., 2013). An 
ultrasound-based sub-study of the SIFAP cohort found > 50% atherosclerotic 
extracranial carotid stenosis in 4.9% of patients under age 45 and 11.0% of 
patients aged 45–55, of which 81% were symptomatic (von Sarnowski et al., 
2013a). Further, intracranial stenoses and occlusions were more frequent than in 
extracranial locations (13.9 vs. 8.9%), with the older group being marginally 
more affected. The majority (88%) of stenoses and occlusions were detected in 
the middle cerebral artery, and the prevalence and age-dependency of posterior 
circulation flow abnormalities were similar to results regarding anterior 
circulation. In the SIFAP Study, the rate of subclinical atherosclerosis was 
significant, and < 50% stenosis was detected in 17% of patients aged 45–55 
years. However, these results may have included some nonatherosclerotic 
stenoses, especially dissection, as these results were ultrasound-based, with 
relatively low specificity (Kittner & Singhal, 2013). 
 
 
2.4.2. Small-artery occlusion 
SAO affects arteries with a diameter less than 400 μm that supply the subcor-
tical region, internal capsule, thalamus, central brainstem, and cerebellum 
(Tatlisumak & Thomassen, 2018). According to the TOAST classification, this 
subtype is clinically manifested by one of the traditional lacunar syndromes, 
and the diagnosis is further supported by the presence of hypertension or diabe-
tes. A radiologic lesion of this subtype should lie in the brainstem or subcortical 
region, with a diameter on CT or MRI being < 1.5 cm (Adams et al., 1993). In 
European young stroke cohorts, 12–14% of patients were found to have stroke 
due to small artery disease (Barlas et al., 2013; Putaala et al., 2009a; Rolfs et 
al., 2013). The MRI analysis of the SIFAP Study patients showed that both 
acute and old lacunar infarcts were more common in men over age 45. Like-
wise, white matter hyperintensities, another manifestation of small artery 
disease, were infrequent in patients under age 45, but thereafter were en-




CE stroke is caused by an embolus originating from a cardiac source. These 
sources are divided according to the risk for ischemic stroke. High-risk sources 
include left atrial and left ventricular thrombus, atrial fibrillation, sick sinus 
syndrome, bioprosthetic and mechanical heart valve, and recent myocardial 
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infarction among others. Mitral annular calcification, PFO, atrial septal 
aneurysm (ASA), and PFO with ASA comprise sources with low or uncertain 
risk (Adams et al., 1993; Ay et al., 2005). CE accounts for 17–20% of ischemic 
strokes in young individuals (Barlas et al., 2013; Putaala et al., 2009a; Rolfs et 
al., 2013). High-risk sources are responsible for 49–53% of cardioembolic 
strokes in young patients, with cardiomyopathy and atrial fibrillation being the 
most frequent entities. PFO constitutes the majority of low-risk group (Barlas et 
al., 2013; Putaala et al., 2009a). The causality of PFO in cardioembolic stroke 
remains debated. However, the RoPE score > seven has been recognized as the 
best cutoff value for identifying young patients in whom PFO is the likely cause 
of stroke (Appendix A; Prefasi et al., 2016). Paradoxical embolism is the most 
widely held explanation for the pathogenetic mechanism in PFO. Other 
mechanisms could be thrombus formation in the interatrial canal or PFO-
triggered arrhythmia (Tatlisumak & Thomassen, 2018). Recently, Pirinen et al. 
(2017) found several electrographic markers, besides AF (atrial fibrillation), 
associated with the cardioembolic stroke subtype in young adults. The strongest 
independent parameters were the P-terminal force in lead V1, defined as the 
negative terminal phase of the P wave, and its combination with left ventricular 
hypertrophy (Pirinen et al., 2017).  
 
 
2.4.4. Stroke of other determined etiology 
This classification group consists of more than 200 causes (Tatlisumak & 
Thomassen, 2018) and accounts for 18–25% of patients in the largest young 
adult cohort studies (Barlas et al., 2013; Putaala et al., 2009a; Rolfs et al., 
2013). The most common cause in this group is cervical artery dissection, being 
responsible for 10–15% of all ischemic strokes in young adults (Barlas et al., 
2013; Putaala et al., 2009a; von Sarnowski et al., 2015). The mean age of 
patients with cervical dissection is 44 years (Debette, 2014). In the Cervical 
Artery Dissections and Ischemic Stroke Patients (CADISP) Study, dissections 
were two times more frequent in the carotid artery than in the vertebral artery, 
while in the SIFAP cohort, both dissection sites were equal (Debette, 2011; von 
Sarnowski et al., 2015). Dissections preferentially arise in the mobile parts of 
arteries (Tatlisumak & Thomassen, 2018). The pathophysiologic mechanism 
seems to be induced by structural and functional changes in the arterial walls. 
Various risk factors have been identified, such as cervical trauma, infection, 
hypertension, and migraine, while hypercholesterolemia and overweight seem 
to be protective factors (Debette, 2014; Debette & Leys, 2009). The outcome of 
cervical dissection is mostly favorable, with a low rate of recurrence and 
mortality.  
In terms of frequency, the next most common causes in this subgroup are 
hereditary and acquired coagulopathies, primary and secondary vasculitides, 
and vasospastic disorders (Barlas et al., 2013; Putaala et al., 2009a). Vascu-
litides can be isolated to the central nervous system (i.e., primary angiitis of the 
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central nervous system) and may either occur in association with a systemic 
disease, such as Takayasu’s arteritis and giant cell arteritis, or result secondarily 
from infections, neoplasms or drugs (Tatlisumak & Thomassen, 2018). Inflam-
matory changes in vessel walls can cause stenosis, occlusion, or aneurysm 
formation. Radiological, laboratory and clinical features, such as headache, 
multifocal strokes, and cognitive decline need to be combined to diagnose 
vasculitis. The only definitive test is brain biopsy, but due to segmental involve-
ment of the vessels, it may result in false negatives.  
Vasospastic disorders include reversible cerebral vasoconstriction syndrome 
(RCVS), migrainous infarction, and hypertensive encephalopathy. RCVS has 
recently gained attention as a cause of young-onset stroke, since it has pre-
viously been underdiagnosed. The mean age of patients with RCVS-related 
stroke was 42 years (Ducros, 2012). RCVS comprises thunderclap headaches 
with or without focal neurological symptoms and transient segmental constric-
tion of the cerebral arteries, which resolve within three months. The usual 
triggers are the postpartum period and use of vasoactive drugs, including illicit 
drugs. Singhal et al. developed diagnostic criteria for RCVS with a 100% 
positive predictive value, which includes either recurrent thunderclap headaches 
or a single thunderclap headache in combination with normal MRI, border zone 
infarcts, or vasogenic edema (Singhal et al., 2013). 
Various monogenic diseases have been identified as a cause of ischemic 
stroke, yet their frequency in large cohorts have been under 1% (Barlas et al., 
2013; Putaala et al., 2009a). The SIFAP Study was a prospective European 
multicenter study that aimed to describe the prevalence of Fabry disease, which 
is an X-linked lysosomal storage disorder, among young patients with cerebro-
vascular events. Ischemic stroke in Fabry disease is caused by an accumulation 
of glycosphingolipids in vessel walls as a result of α–galactosidase A gene 
defect. A definite Fabry diagnosis was reported in 0.5% of the cohort, with a 
probable diagnosis supported by biochemical analysis found in another 0.4% 
(Rolfs et al., 2013). A study from Canada found an even lower prevalence 
(Lanthier et al., 2017). Strokes associated with Fabry disease are generally of 
mild severity and have a good prognosis (Lanthier et al., 2017; Rolfs et al., 
2013).  
The Lombardia Genetics of Stroke (GENS) Study included cryptogenic 
stroke patients with high probability for five monogenic diseases: cerebral auto-
somal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL), mitochondrial encephalopathy, lactic acidosis, and stroke-like 
episodes (MELAS), Fabry disease, Marfan syndrome, and hereditary cerebral 
amyloid angiopathy (Bersano et al., 2016).  The included patients were either 
under age 55, lacked common vascular risk factors, had a family history of 
stroke, or presented with at least two specific clinical features of a genetic 
disorder. They were then tested only for suspected diagnosis. Using this 
algorithm, the diagnostic yield for the mentioned monogenic diseases was 7%. 
A positive family history was identified as the only independent predictor of an 
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underlying genetic disease. Thus, it seems practical to apply only narrow 
phenotype-based screening for young patients with cryptogenic stroke.  
 
 
2.4.5. Stroke of undetermined etiology 
In the largest studies of young stroke patients, the prevalence of this etiologic 
subgroup ranges from 33% to 40% (Barlas et al., 2013; Putaala et al., 2009a; 
Rolfs et al., 2013), whereas the highest reported prevalence is 62% (Leys et al., 
2002). It was hypothesized that most cryptogenic strokes (i.e., excluding those 
with incomplete evaluation or two concurrent causes) had an embolic origin, 
and as a result, the concept of embolic stroke of undetermined etiology (ESUS) 
was introduced in 2014 (Hart et al., 2014). This concept comprises strokes with 
clinical and radiological indications of embolism without a verified source. By 
definition, it is a non-lacunar stroke with absent atherosclerotic stenosis ≥ 50% 
in the arteries supplying the infarcted area, and no major cardioembolic sources 
or other specific causes. The diagnostic workup of ESUS is straightforward, and 
its required procedures are a brain computed tomography or MRI, 12-lead 
electrocardiogram, precordial echocardiography, 24-hour automated cardiac 
rhythm monitoring, and imaging of the cervical and brain arteries. The sources 
of embolism in ESUS can be cardiogenic (e.g., atrial cardiopathy, left ventri-
cular dysfunction, valvular disease, and covert atrial fibrillation), arteriogenic 
(e.g., non-stenotic carotid plaques, aortic atheroma), paradoxical (patent fora-
men ovale), or cancerogenic. However, as minor risk sources, their presence 
does not automatically mean that they have causal influence on stroke (Hart et 
al., 2014; Ntaios, 2020). In a Portuguese study, the majority (82%) of young 
patients with cryptogenic stroke were ESUS (Ladeira et al., 2015). In a 
multiethnic global database, 24% of all young ischemic stroke cases fulfilled 
the ESUS criteria (Perera et al., 2018), and 63% of ESUS patients had at least 
one low risk embolic source and 14% had two (Perera et al., 2018). In a meta-
analysis, the annual stroke recurrence rate in a sample of young ESUS patients 
was found to be 4.5% during a follow-up period of 2.7 years (Hart et al., 2017). 
After two negative clinical trials of non-vitamin K antagonist oral anticoagu-
lants (Diener et al., 2019; Hart et al., 2018), the concept of ESUS has been 
criticized, as it has failed to demonstrate a link with certain treatment strategies, 
similar to the traditional concept of cryptogenic stroke (Fuentes et al., 2020). 
Fuentes et al. suggested that the current diagnostic work-up for ESUS should be 
widened (Fuentes et al., 2020). An ongoing international study Searching for 
Explanations for Cryptogenic Stroke in the Young: Revealing the Triggers, 
Causes, and Outcome (SECRETO) aims to find pathogenetic mechanisms for 
cryptogenic stroke (Putaala et al., 2017). The study emphasis is on triggers and 
subclinical risk factors of stroke, thorough cardiac investigations, abnormalities 
of hemostasis and genetic analysis.  




2.5.1. Acute treatment 
Thrombolysis with intravenous alteplase is the mainstay therapy for acute ische-
mic stroke. According to a recent large observational study, patients aged 18–40 
years were more often treated with intravenous thrombolysis than their older 
counterparts (12.5 vs. 8.8%) and young patients were also less likely to have 
contraindications for this treatment (Dodds et al., 2019). Young adults benefit 
from intravenous alteplase compared with those not receiving alteplase after 
being matched for all relevant factors (Putaala et al., 2009b). Compared with 
older patients, the outcome of thrombolysis is more favorable in young adults in 
terms of less frequent symptomatic intracerebral hemorrhage and better func-
tional recovery (Dodds et al., 2019; Poppe et al., 2009; Putaala et al., 2009b; 
Toni et al., 2012).  
Endovascular thrombectomy is an evidence-based therapy for large vessel 
occlusion that has been used since 2015 (Goyal et al., 2016), yet data on young 
adults are scarce. Young patients seem to achieve a more favorable outcome 
with this treatment. In a single-center study, patients under age 50 had fewer 
peri- and post-procedural complications than older patients, and 72% had a 
modified Rankin score of 0–2 at 3 months (Danière et al., 2015).  
Several prediction scores have emerged that help predict post-stroke infec-
tions. Age, Atrial fibrillation, Dysphagia, Sex, and Stroke Severity (A2DS2) 
score was found to have the best performance in predicting post-stroke pneu-
monia (Helmy et al. 2016), one of the most common complications after stroke 
(Kumar et al., 2010). A meta-analysis of preventive antibiotic therapy in 
patients with ischemic and hemorrhagic stroke did not find either reduced 
mortality or functional disability (Vermeij et al., 2018). Preventive antibiotics 




2.5.2. Primary and secondary prevention 
Data on prevention of ischemic stroke in young adults are also limited. The 
representation of young people in stroke clinical trials is low, and most data 
come from observational studies. Accordingly, no guidelines tailored speci-
fically for young adults are available, and both primary and secondary preven-
tion follow general recommendations.  
Considering that secondary prevention is life-long, adherence to it from a 
young age may be challenging. The use of antihypertensive medication was 
suboptimal in one-third of Finnish young ischemic stroke patients, for whom it 
was initially prescribed, resulting in higher mortality and recurrent cerebro-
vascular event rates compared to antihypertensive medication users (van Don-
gen et al., 2019). The adherent group had 33% absolute risk reduction in 
mortality after one year compared to non-adherent patients. Similarly, in an 
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Italian study, discontinuation of antihypertensive or antiplatelet therapy after 
ischemic stroke was an independent predictor of recurrent vascular events in 
young adults (Pezzini et al., 2014).  
More than half of the young patients and 41% with dyslipidemia did not use 
statins. However, statin users had lower all-cause mortality and recurrent stroke 
rates than those who did not use them (van Dongen et al., 2019a). Young 
patients benefit from statins regardless of their inconsistent use, and the pre-
sence or absence of dyslipidemia or stroke etiology (Putaala et al., 2011).  
The Cervical Artery Dissection in Stroke Study (CADISS) where study pa-
tients’ mean age was 49 years, compared the efficacy of antiplatelet therapy 
with anticoagulants in preventing a subsequent stroke in extracranial cervical 
artery dissection. After three months, the trial found no difference in efficacy 
between the two treatment modalities. One notable limitation of this trial was its 
inability to detect dissection in 20% of cases during later review (The CADISS 
Trial Investigators, 2015).  
A meta-analysis of PFO-related stroke concluded that after 3.7 years, the 
rate of ischemic stroke recurrence was lower in the closure arm than in the 
medical therapy group, with the number needed to treat 46.5. At the same time, 
there was a higher rate of new-onset atrial fibrillation in the interventional 
group. A sub-analysis revealed that percutaneous closure was efficacious only 
with significant right-to-left shunt and/or the presence of an atrial septal 
aneurysm. In low-risk PFO, the treatment modalities did not show any 
difference (Ntaios et al., 2018). Recent secondary prevention guidelines suggest 
closure of PFO in patients who are 18–60 years old, have nonlacunar stroke 
with no identified cause and PFO with high risk characteristics (Kleindorfer et 
al., 2021).  
 
2.6. Outcome of Stroke 
2.6.1. Mortality 
In studies conducted in the past two decades, 30-day mortality among young 
adults with ischemic stroke ranges from 0% to 3.6% (Greisenegger et al., 2011; 
Naess et al., 2002; Putaala, et al., 2009; Renna et al., 2014; Rutten-Jacobs, et al., 
2013) and the 1-year mortality from 4.5% to 6.3% (Leys et al., 2002; Marini et 
al., 1999; Putaala, et al., 2009; Varona et al., 2004; Waje-Andreassen et al., 
2007). After the first year, the mortality rate decreases to 0.8% to 1.9% annually 
(Leys et al., 2002; Marini et al., 1999; Putaala, et al., 2009; Varona et al., 2004; 
Waje-Andreassen et al., 2007), and thus the 5- and 10-year cumulative mortality 
has been reported to range from 5.8% to 11.0% (Greisenegger et al., 2011; 
Naess et al., 2004; Putaala, et al., 2009; Rutten-Jacobs, et al., 2013; Varona et 
al., 2004) and from 12.0% to 12.4% (Naess et al., 2004; Rutten-Jacobs, et al., 
2013; Varona et al., 2004), respectively. The 20-year cumulative mortality in 
Spain was 21.7% (Varona et al., 2004), and in the Netherlands among 30-day 
survivors was found to be 26.8% (Rutten-Jacobs, et al., 2013). Long-term 
 
24 
observed mortality among young ischemic stroke patients is 4–15 times higher 
than the expected mortality in the general population (Aarnio et al., 2014; Giang 
et al., 2013; Marini et al., 1999; Rutten-Jacobs et al., 2013; Waje-Andreassen et 
al., 2007). In a Swedish study mortality after ischemic stroke decreased by 32% 
in young men and by 45% in women between 1987 and 2006 (Giang et al., 
2013). In Estonia, the 5- and 7-year mortality rates among ischemic stroke 
patients under age 45 were high (25%) and not significantly different between 
1991–1993 and 2001–2003 (Vibo et al., 2012). 
Long-term mortality has been associated with increasing age, recurrent 
stroke, more severe stroke, each of the TOAST subgroups, but particularly, 
large artery atherosclerosis and cardioembolism, coronary artery disease, heart 
failure, peripheral artery disease, diabetes, active malignancy, epilepsy, pre- and 
post-stroke infection, high alcohol consumption, and being single (Aarnio et al., 
2014; Heikinheimo et al., 2013; Marini et al.,1999; Putaala et al., 2009; Rutten-
Jacobs et al., 2013; Waje-Andreassen et al., 2007). Two studies have also 
shown that a higher number of vascular risk factors at the time of index stroke 
correlated with higher long-term mortality (Naess et al., 2013; Putaala et al., 
2012).  
Regarding the causes of death, cardiac diseases were attributable in 20–46%, 
recurrent ischemic stroke in 7–16%, malignancies in 12–22%, and infections in 
4–16% of cases (Greisenegger et al., 2011; Naess et al., 2004; Putaala et al., 
2009; Rutten-Jacobs et al., 2013).  
 
 
2.6.2. Recurrent vascular events 
In the first year after an initial ischemic stroke, the risk of a recurrent stroke 
ranges from 1.4% to 3.6%, which substantially decreases in the following years 
(Leys et al., 2002; Pezzini et al., 2014; Putaala et al., 2010; Varona et al., 2004).  
The rate of other vascular events during this period is comparatively low (Leys 
et al., 2002; Pezzini et al., 2014; Putaala et al., 2010). In the long term, the risk 
of vascular events remains increased. The cumulative risk of ischemic stroke 
and composite vascular events was 19% and 36%, respectively, after 15 years in 
the Finnish study (Aarnio et al., 2016). In the Dutch cohort the rate of recurrent 
stroke and all vascular events after 20 years was 9% and 33%, respectively, and 
after 25 years, 30% and 45% respectively (Arntz et al., 2016; Rutten-Jacobs et 
al., 2013a). Stroke recurrence is higher in older patients, those with traditional 
vascular risk factors, previous transient ischemic attack (TIA), and patients with 
either atherothrombotic, cardioembolic, or lacunar stroke (Aarnio et al., 2016, 
2016; Rutten-Jacobs et al., 2013a). Similar to mortality rates, a higher number 
of vascular risk factors correlates with a higher stroke recurrence rate (Putaala 
et al., 2010). Notably, stroke due to arterial dissection has a very low recurrence 
rate (Aarnio et al., 2016).  
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2.6.3. Functional outcome 
Disability. The most frequently used functional outcome measure in stroke pa-
tients is the modified Rankin Scale (mRS), which assesses functional indepen-
dence on a 7-level scale (0 = no symptoms, 6 = death; Appendix C). A Swiss 
study revealed that at 3–6 months after stroke, 64% of surviving young patients 
had no or minimal deficit (mRS 0–1) and 85% were independent (mRS 0–2), 
and the results did not change from short-term to long-term (Goeggel Simonetti 
et al., 2015). Young patients have significantly higher odds for good short-term 
recovery compared to older patients—the difference between those who are 18–
35 years old and 76–86 years old is ten-fold (Knoflach et al., 2012). 
In long-term studies, 58–84% of survivors achieved excellent outcomes 
(mRS 0–1) and 83–93% good outcome (mRS 0–2) after 3–12 years (Goeggel 
Simonetti et al., 2015; Leys et al., 2002; Spengos & Vemmos, 2010; Synhaeve 
et al., 2014; Varona et al., 2004). Poor functional outcomes (mRS > 2) have 
been associated with increased age, female sex, more severe stroke, cardio-
vascular disease, diabetes, and high alcohol consumption (Goeggel Simonetti et 
al., 2015a; Leys et al., 2002; Naess et al., 2004; Synhaeve et al., 2014).  
Health-related quality of life (HRQOL). The HRQOL measure evaluates 
stroke outcomes from the patients’ perspective and rates physical, emotional, 
social, and other domains. The most affected domains in young patients are 
physical function, satisfaction with social roles, and executive function (de 
Bruijn et al., 2015a; Naess et al., 2006). In a Korean study, HRQOL was signi-
ficantly better in young patients compared to older patients (Kim et al., 2005), 
while a USA study did not show significant differences between the two groups 
(Lisabeth et al., 2018). The independent factors that have been associated with 
low HRQOL among young stroke survivors include depression, fatigue, 
unemployment, higher mRS, motor dysfunction, and dysarthria (de Bruijn et al., 
2015; Kim et al., 2005; Naess et al., 2006). A study from the Netherlands that 
included young patients with mild stroke reported that time since the event had 
no significant influence on HRQOL (de Bruijn et al., 2015).  
 
 
2.6.4. Psychosocial complications 
Although prognosis in terms of mortality, cardiovascular morbidity, and motor 
recovery in young stroke is relatively favorable compared to older patients, the 
psychosocial complications of stroke are widespread and affect young people’s 
lives for years after initial stroke.  
Cognitive impairment. A study from China found that cognitive dysfunc-
tion in the acute phase in young patients was worse in those with a higher 
number of vascular risk factors (Lu et al., 2016). After 11 years, cognitive 
impairment was present in 34.5% of young ischemic stroke patients in a Dutch 
cohort, with processing speed, working memory, and attention being the most 
commonly affected domains (Schaapsmeerders et al., 2013). Left supratentorial 
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infarction was associated with worse outcomes. Mild and focal ischemic strokes 
tend to affect multiple cognitive domains in young patients compared to older 
patients who primarily have disturbances in executive function (Maaijwee et al., 
2014; Sachdev et al., 2004).  
Depression/anxiety. Post-stroke depression and anxiety are approximately 
twice as common in young patients than in older stroke patients (Kapoor et al., 
2019). It is probably due to demanding family and work responsibilities that 
young people feel the impact of stroke more acutely. Six years after stroke, 
28.6% of young patients in a Norwegian population-based cohort had clinical 
depression; of note, most (88%) had a mild form (Naess et al., 2005a). During 
the second follow-up, the prevalence of self-assessed depression was 29.2% 
(Waje-Andreassen et al., 2013). In a Dutch study, the risk of depressive symp-
toms (19.5%) and anxiety (23.0%) was five times higher in stroke survivors 
than in controls after a 10-year follow-up period (Maaijwee et al., 2016). The 
prevalence of depression and anxiety was not associated with stroke location or 
etiology, except that anxiety was less common in stroke of rare etiology. In 
general, post-stroke depression and anxiety share the same risk factors – low 
education, unemployment, alcohol abuse and a history of depression (Maaijwee 
et al., 2016; Naess et al., 2005b). Additionally, depression was predicted by 
stroke severity Naess et al., 2005b). Depressive symptoms and anxiety affect 
the functional outcomes of young patients, and both have been correlated with 
poor motor function (mRS > 2) and worse performance in more complex tasks 
(instrumental activities of daily living scale < 8) even a decade after the initial 
stroke (Maaijwee et al., 2016).  
Fatigue. The prevalence of fatigue among stroke survivors is 41–51.3% 
measured 6–10 years after stroke compared to 18–23% in matched controls 
(Maaijwee et al., 2016; Naess et al., 2006). Mechanisms contributing to fatigue 
are poorly understood, as some studies have found it to be more prevalent in 
infratentorial and basal ganglia lesions (Snaphaan et al., 2011; Tang et al., 
2010), while others have found no association at all (Maaijwee et al., 2015). 
The risk of fatigue is higher in patients with depression, anxiety, and recurrent 
stroke, and its presence is independently associated with lower quality of life, 
poor functional outcome, and cognitive impairment (Maaijwee et al., 2015; 
Naess et al., 2005, 2006).  
 
 
2.6.5. Return to work 
Returning to work is one of the best signs of excellent recovery after stroke. 
However, despite relatively good functional recovery among young patients, 
both their short- and long-term employment rates remain low. Of note, the 
definition of work has varied across studies, and patients’ pre-stroke occupa-
tional status has not always been mentioned. In a Swiss cohort, the employment 
rate was 56% after three months; however, 57% worked part-time (Goeggel 
Simonetti et al., 2015a). In the Finnish study, 41% of those who worked full-
 
27 
time prior to stroke had returned to work after 6 months (Kauranen et al., 2013). 
In long-term studies, the employment rate has ranged from 42% to 53% after 
more than a decade after stroke (Varona et al., 2004; Waje-Andreassen et al., 
2013). Factors predicting return to work are male sex, younger age, good 
functional recovery, normal cognition, and intravenous thrombolysis (vs. no 
thrombolysis; Kauranen et al., 2013; Stefanovic Budimkic et al., 2016; Varona 
et al., 2004; Waje-Andreassen et al., 2013).  
 
 
2.7. Summary of the Literature Review 
The incidence of young-onset ischemic stroke has risen worldwide. Frequently 
this has been credited for the increasing prevalence of modifiable well-docu-
mented vascular risk factors. The association studies have demonstrated that 
among these risk factors behavioral factors explain most ischemic strokes in the 
young. However, for around 40% of young patients the etiology remains un-
known, resulting in a classification of cryptogenic stroke.  
The burden of ischemic stroke has several dimensions, including mortality, 
disability, health-related quality of life, and others. While mortality among 
young adults has decreased in high-income countries over the last decades, it is 
still considerably higher compared with age-matched stroke-free counterparts. 
Young patients also show markedly affected HRQOL with the most prominent 
impairments in physical function, satisfaction with social roles, and executive 
function. 
However, these data mainly come from Western and Northern European and 
North American cohorts, but reports on young patients from Eastern Europe are 
scarce. Recent studies from Estonia have found younger age at stroke than in 
Western European countries and high long-term mortality among ischemic 
stroke patients aged 15–44 years, which did not change between 1991 and 2003. 
It is therefore, justified to find contributors for high incidence of young-onset 
stroke and to update mortality data. Several predictors of long-term mortality 
have been identified, but determinants of 30-day mortality among young 
ischemic stroke patients have not been analyzed. Likewise, data regarding long-
term HRQOL and its predictors in this specific population are limited and need 
to be updated to better plan health policies. Consequently, we hypothesized that 
traditional vascular risk factors were highly prevalent in Estonia and started to 
accumulate at an early age. Our hypothesis was that early risk factor accumu-
lation would contribute to high mortality of ischemic stroke in young people. 
We also hypothesized that long-term HRQOL after young-onset ischemic 
stroke was lower than in the general population.  
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3. AIMS OF THE STUDY 
1. To analyze the risk factors and etiology of young first-ever ischemic stroke 
patients in Estonia (Paper I).  
2. To determine the short- and long-term mortality, clinical determinants, and 
causes of death in young patients with ischemic stroke (Paper II).  
3. To assess the long-term HRQOL in a young ischemic stroke cohort and to 
























4. PARTICIPANTS AND METHODS 
This study was approved by the Research Ethics Committee of the University of 
Tartu (Permission No. 219/T-25) and Data Protection Inspectorate of the 
Republic of Estonia (Permission No. 2.2.–3/13/595r). Informed consent was ob-
tained from the postal questionnaire participants by means of reply mail.  
 
 
4.1. Data Collection 
We conducted a retrospective study of young stroke patients, aged 18–54 years, 
who were admitted to Tartu University Hospital and North Estonia Medical 
Centre from 2003 to 2012 for their first ischemic stroke. These two hospitals are 
the largest and only tertiary health care providers in Estonia. Although stroke 
patients are treated in six hospitals in Estonia, more than 60% of the cases are 
treated either in Tartu University Hospital or North Estonia Medical Centre. 
The cases were identified using the International Classification of Diseases, 
Tenth Revision (ICD-10) codes I63.0–I63.9 with the help of an electronic dis-
charge registry (Figure 1). Ischemic stroke was defined as a focal neurological 
deficit of acute onset which lasted more than 24 hours or evidence of acute 
brain ischemia on neuroimaging studies, when symptoms lasted less than 24 
hours (Sacco et al., 2013). Patients with transient ischemic attack, iatrogenic 
stroke, cerebral venous thrombosis, or hemorrhagic stroke were excluded from 
the study. We reviewed all the medical records and registered data regarding 
stroke symptoms and severity, risk factors, etiology, radiological features, and 
laboratory tests (Paper I). 
 We obtained survival data and postal addresses of individual patients from 
the Estonian Population Registry (Papers II and III) and the causes of death for 
deceased patients from the Estonian Causes of Death Registry (Paper II). 
To assess HRQOL (Paper III), we distributed a questionnaire by postal mail 
to patients who had survived. The questionnaire comprised a selection of 
questions from the 2012 Health Behavior among Estonian Adult Population 
Study, including their height and weight (Tekkel & Veideman, 2013), three-
level version of EQ-5D (EQ-5D-3L; Appendix E; EuroQol Research Founda-
tion, n.d.), and a questionnaire that provided a modified Rankin score (Appen-
dix D; Patel et al., 2012). Patients were asked to report recurrent vascular 
events, post-stroke epilepsy, and employment. To all those who did not reply, 
we sent a reminder letter three months later and, if necessary, again two months 
later.  
 For the control group, we requested data from the 2012 Health Behavior 
among Estonian Adult Population Study (Tekkel & Veideman, 2013), which is 
conducted every second year by the Department of Epidemiology and Biosta-
tistics at the National Institute for Health Development in Estonia. It is a ques-
tionnaire survey distributed through the postal mail and includes a random 









































































































































































































































































































































































































































































































The five dimensions of EQ-5D-3L are mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression (Appendix E). Each dimension is 
graded on a three-level scale as: 1 = no problems, 2 = some problems, and 3 = 
extreme problems. These responses can produce 243 different combinations, 
known as health profiles. A full health state is characterized by the combination 
“1-1-1-1-1” and the worst profile as “3-3-3-3-3.” A single utility score which 
ranged from -0.523 to 1.0 was then calculated for each health profile based on 
population norms, where 1 represented perfect health and negative values repre-
sented a condition worse than death. For further analysis of each dimension, we 
dichotomized the EQ-5D-3L levels into no problems (Answer 1) and problems 
(Answers 2 and 3). 
  
4.2. Diagnostic Workup 
4.2.1. Etiology 
The etiologic evaluation was considered complete when all the following were 
performed: 1) brain imaging by computed tomography and/or MRI; 2) vascular 
imaging of extra- and/or intracranial arteries by ultrasonography, computed 
tomography angiography, magnetic resonance angiography, and/or catheter 
angiography; and 3) cardiac evaluation by echocardiography. An electrocardio-
gram (ECG) was performed on all patients, and 24-hour Holter ECG recording 
was performed when considered clinically necessary. Stroke subtypes were then 
classified using the TOAST criteria.  
 
 
4.2.2. Risk factors 
Ischemic stroke risk factors were registered and divided into well-documented 
and less well-documented groups (Meschia et al., 2014). Hypertension was 
defined as systolic blood pressure > 140 mmHg and/or diastolic blood pressure 
> 90 mmHg before stroke, seven days after stroke, or receiving antihyperten- 
sive treatment. The criteria for dyslipidemia were serum total cholesterol  
≥ 5.0 mmol/L, low-density lipoprotein cholesterol ≥ 3.0 mmol/L, high-density 
lipoprotein cholesterol < 1.0 mmol/L, or previous cholesterol-lowering therapy. 
Diabetes mellitus was diagnosed on the basis of one of the following criteria: 
fasting plasma glucose ≥ 7.0 mmol/L, two-hour post-glucose challenge value  
≥ 11.1 mmol/L, glycated hemoglobin ≥ 6.5%, or the patient took antidiabetic 
medication. Coagulation testing was done selectively and included the fol-
lowing markers: fibrinogen, D-dimer, homocysteine, protein C and S, activated 
protein C resistance, factor V Leiden, prothrombin G20210A, antithrombin III, 
lupus anticoagulant, and anti-beta2-glycoprotein I antibodies. Smoking, heavy 
drinking, and illicit drug use were listed as risk factors if they were identified in 
the medical records. Similarly, the patient was considered obese if indicated in 
the medical records or if the body mass index was ≥ 30 kg/m2. The diagnosis of 
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PFO and ASA was confirmed using transesophageal echocardiography. The 
term structural cardiac diseases included acute myocardial infarction, cardio-
myopathy, valvular heart disease, PFO with ASA, and cardiac tumors.  
Complete blood count was assessed on admission or in the first 24 h after 
admission. Normal white blood cell (WBC) count was recorded if the values 
were between 4.0–8.9 × 109/L. Preceding infection was defined as any infection 
in the month before the ischemic stroke. Post-stroke infection was defined as 
any acute infection with clinical signs acquired during the first seven days after 
admission that was confirmed either by radiological and/or laboratory findings. 
 
4.2.3. Stroke severity 
Stroke severity was assessed according to the National Institutes of Health 
Stroke Scale (NIHSS) and was stratified as: mild (0–6), moderate (7–15), and 
severe (16–42; Appendix C). If the NIHSS score was unavailable, it was 
retrospectively determined on the basis of neurological examination using a 
validated algorithm (Williams et al., 2000).  
 
 
4.3. Statistical Analyses 
Chi-square tests, Fisher’s exact tests, or Monte Carlo simulations were used to 
examine the differences between groups with categorical variables. Continuous 
variables were compared using the independent samples 𝑡-test (Papers I–III). 
The Kaplan-Meier method was used to calculate the cumulative mortality risks 
(Paper II). The univariate and multivariate analysis of the risk factors of 30-day 
mortality was found using logistic regression and the risk factors of 5-year 
mortality by the Cox proportional hazards models (Paper II). The EQ-5D-3L 
dimensions were compared between patients and controls with logistic regres-
sion. Due to right censoring, the tobit regression was applied for analyzing the 
EQ-5D-3L utility score (Paper III). Only the variables with p value of < 0.05 in 
the adjusted univariate analysis were entered to the backwards stepwise 
multivariate analysis (Papers II and III). 
All statistical analyses were performed using R software (R Core Team, 





5.1. Risk Factors and Etiology of Young Ischemic Stroke 
Patients (Paper I) 
5.1.1. Demographics  
Our registry comprised of 741 patients (men = 67.3%, n=500; Mage = 46.9 years, 
SD = 7.4). Of these, 225 patients (30.1%) were aged between 18–44 years and 
516 patients (69.9%) were aged between 45–54 years. Men predominated in all 
5-year age bands (Figure 2). There were no significant differences in the age 
distribution between men and women.  
Brain imaging was performed in all patients. Computed tomography was 
done in 720 patients (97%) and MRI in 186 patients (25.0%), extra- and/or 
intracranial vascular imaging was performed in 549 patients (74.1%) and 
transthoracic echocardiography was done in 520 patients (70.2%), of which 100 
patients (19.2%) were also studied with transesophageal echocardiography. 































5.1.2 Risk factors and severity of ischemic stroke  
The prevalence of well-documented risk factors was 83.1% (n=616), and it was 
significantly higher in men (n=436, 87.2% vs. n=180, 74.7%; p < 0.001) and in 
the older age group (n=454, 88.0% vs. n=162, 72.0%; p < 0.001). The most 
frequent risk factors were hypertension (n=392, 52.9%), dyslipidemia (n=337, 
45.5%), and smoking (n=257, 34.7%). Men had statistically more frequently 
atrial fibrillation, coronary heart disease, and heart failure and were more often 
smokers than women. Patients aged over 44 years suffered more often from 
dyslipidemia, hypertension, diabetes mellitus, coronary heart disease, and atrial 
fibrillation (Table 1, Figure 3).  
The overall prevalence of less well-documented risk factors did not show 
any sex disparity, yet women more often had migraine and recent infection, 
whereas men more frequently were heavy alcohol users. The prevalence of less 
well-documented risk factors was significantly higher in the younger age group 
(n=91, 40.4% vs. n=132, 25.6%; p <0.001; Table 1, Figure 3). For 84 patients 
(11.3%), including 49 (9.8%) men and 35 (14.5%) women, no risk factors were 
identified.  
The majority of patients suffered a mild stroke; however, the stroke was 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3. Prevalence of various vascular risk factors by age.  
 
 
5.1.3. Etiology of ischemic stroke 
CE (n=127, 17.1%) and LAA (n=106, 14.3%) were the most frequently 
reported causes of ischemic stroke (Table 1). Regarding CE, AF was the most 
common source of embolism (n=61, 48%; Table 2). CE and LAA were 
followed by SAO (n=66, 8.9%) and ODE (other definite etiology; n=63, 8.5%), 
the group in which cervical artery dissection was the leading cause of stroke 
(n=25, 40%; Table 3). Almost one in three patients had incomplete evaluation, 
20.5% (n=152) had no obvious cause despite extensive investigations (i.e., 
cryptogenic stroke), and 0.3% (n=2) had two or more possible causes of stroke. 
Overall, the distribution of TOAST subgroups was statistically different 
between age and sex groups (p < 0.001; Table 1, Figure 4). Comparison of 
TOAST subgroups revealed that ODE was more frequent in women (p = 0.003) 

























Table 2. Sources of cardioembolism in first-ever stroke patients. 
n=127 %
High-risk sources 
Atrial fibrillation  61 48%
Recent myocardial infarction 12  9%
Cardiomyopathy 7  6%
Endocarditis 7  6%
Sick sinus syndrome 5  4%
Intracardiac thrombus  5  4%
Mechanical heart valve 4  3%
Rheumatic valve disease  4  3%
Congestive heart failure 3  2%
Ventricular wall akinesia  2  2%
PFO + ASA 2  2%
Myxoma 1  1%
Congenital cardiac malformation  1  1%
Sources of low or uncertain risk
PFO 7  6%
Hypokinetic left ventricular segment 4  3%
ASA 1  1%
 
 




Hematologic disease 10 16%
Active malignancy 7 11%
Vasculitis  5 8%
Migrainous infarction 5 8%
Illicit drug use 3 5%
Pregnancy and puerperium related 3 5%
Vascular malformation/aneurysm 2 3%
Factor V Leiden 1 2%
Protein C deficiency 1 2%




Figure 4. Frequency of etiologic subgroups in age groups of 18–34, 35–44, and 45–54 
years. Cryptogenic stroke and incomplete evaluation comprise undetermined etiology 
according to TOAST.  
 
 
5.2. Short- and Long-Term Mortality, Clinical Determinants, 
and Causes of Death (Paper II) 
The mean follow-up time in the survival study was 10.8 (range 6.1–16.0) years. 
The baseline characteristics of patients who died within 30 days and between 31 
days and five years and of those who survived beyond five years are shown in 
















































days, n (%)  
Deceased 
between 31 
days and five 
years, n (%) 
Survived beyond 
five years, n (%) 
 n = 33 (4.5) n = 91 (12.3) n = 614 (83.2) 
Age, years 48.1±5.9 48.5±6.0 46.6±7.6 
Men 24 (72.7) 75 (82.4) 400 (65.0) 
Age groups       
      18–44 years 6 (18.2) 21 (23.1) 195 (31.7) 
      45–54 years 27 (81.8) 70 (76.9) 420 (68.3) 
Risk factors       
      Hypertension 11 (33.3) 47 (51.6) 333 (54.1) 
      Dyslipidemia 2 (6.1) 33 (36.7) 302 (49.1) 
      Smoking  5 (15.2) 30 (32.2) 222 (36.1) 
      Obesity 0 (0.0) 4 (4.4) 68 (11.1) 
      Diabetes mellitus 5 (15.2) 12 (13.2) 65 (10.6) 
      Coronary heart disease 7 (21.2) 15 (16.7) 45 (7.3) 
      Atrial fibrillation 1 (3.0) 14 (15.6) 44 (7.2) 
      Heart failure 1 (3.0) 14 (15.6) 33 (5.4) 
      Structural cardiac diseases 5 (15.2) 12 (13.3) 22 (3.6) 
      PAD 0 (0.0) 1 (1.1) 7 (1.1) 
      High alcohol consumption  11 (33.3) 21 (23.3) 98 (15.9) 
WBC count >9 × 109/L 24 (72.7) 38 (42.2) 198 (32.2) 
Post-stroke infection 11 (33.3) 21 (23.3) 40 (6.5) 
Sepsis 2 (18.2) 2 (9.5) 0 (0.0) 
Pneumonia 7 (63.6) 9 (42.9) 23 (57.5) 
Genitourinary 0 (0.0) 6 (28.6) 13 (32.5) 
Skin 1 (9.1) 0 (0.0) 0 (0.0) 
Others 1 (9.1) 4 (19.0) 4 (10.0) 
Stroke severity        
Mild (NIHSS 0–6) 8 (24.2) 48 (52.7) 435 (70.7) 
Moderate (NIHSS 7–15) 6 (18.2) 31 (34.1) 123 (20.0) 
Severe (NIHSS ≥16) 19 (57.6) 12 (13.2) 57 (9.3) 
Stroke subtypes       
LAA 4 (12.1) 9 (9.9) 93 (15.1) 
SAO 0 (0.0) 8 (8.8) 59 (9.6) 
CE 7 (21.2) 30 (33.0) 90 (14.6) 
ODE 7 (21.2) 4 (4.4) 52 (8.5) 
UND 15 (45.5) 40 (44.0) 321 (52.2) 
Two or more causes 0 (0.0) 0 (0.0) 2 (0.3) 
Negative evaluation 0 (0.0) 8 (8.8) 143 (23.3) 
Incomplete evaluation 15 (45.5) 32 (35.6) 176 (28.6) 
Note. Data are expressed as mean ± standard deviation or n (%); CE, cardioembolism; 
LAA, large artery atherosclerosis; NIHSS, National Institutes of Health Stroke Scale; 
ODE, stroke of other determined etiology; PAD, peripheral artery disease; SAO, small-
artery occlusion; UND, stroke of undetermined etiology, WBC, white blood cell. 
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5.2.1. Thirty-day mortality 
There were 33 deaths during the initial 30 days; thus, the 30-day mortality rate 
was 4.5% (95% CI [3.0%, 6.0%]; Table 5). The causes of death included index 
ischemic stroke, (n = 27, 81.8%), cardiac and other vascular causes (n = 2, 
6.1%), malignancy (n = 2, 6.1%), trauma (n = 1, 3.0%), and infection (n = 1, 
3.0%). Severe stroke and post-stroke infections were independently associated 
with death during the first 30 days (Table 6).  
 
 
5.2.2. Long-term mortality 
Ninety-one patients died between 30 days and five years after the index stroke. 
The cumulative mortality rate at five years was 16.8% (95% CI [14.1%, 
19.5%]; Table 5, Figure 4A). The 5-year mortality was significantly higher 
among men (p < 0.01) and in patients over 44 years (p = 0.04; Table 5, Figure 
5B & 5C). There was a significant difference in the mortality rate between 
younger and older women (p <0.01), but not in men (p = 0.67; Figure 5E and 
5D, respectively). Regarding stroke etiology, the highest mortality rate was 
found in the cardioembolic group (Figure 6).  
The causes of death in the 30-day survivors who died within five years (n = 
91) included cardiac and other vascular causes (n = 33, 36.3%), infection and 
miscellaneous causes (e.g., diabetes, hepatic cirrhosis, pancreatitis, and 
epilepsy; n = 19, 20.9%), recurrent stroke (n = 17, 18.7%), malignancy (n = 13, 
14.3%), and trauma and poisoning (n = 9, 9.9%). There were no significant 
differences in the causes of death between men and women (Fisher’s exact test 
p = 0.95) and between younger (18–44 years) and older patients (> 44 years) 
(Fisher’s exact test p = 0.12). However, in the younger age group, none died of 
malignancy.  
In the Cox proportional hazards model, the independent determinants of 
long-term mortality were post-stroke infection, structural cardiac disease, and 
moderate stroke severity (Table 6).  
 
 
Table 5. Cumulative mortality in different groups and time points. 
 30-Day Mortality 5-Year Mortality 
 n % 95% CI p-value n %     95% CI p-value 
All 33 4.5  3.0–6.0  124 16.8   14.1–19.5  
Men 24 4.8   2.9–6.7 0.5 99 19.7  16.1–23.1 <0.01 
Women 9 3.7  1.3–6.1 25 10.8 6.8–14.6 
Age 18–
44 years 
6 3.1 0.8–5.4 0.25 27 12.6  8.1–16.8 0.04 
Age 45–
54 years 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 6. Cumulative mortality in the etiologic TOAST subgroups.  
 
 
5.3. Determinants of Long-Term Health-Related Quality of 
Life (Paper III) 
In total, 352 patients (60.5% response rate, 63.1% male, n= 222; median age at 
follow-up = 54.0 years, range 27–65 years) and 2304 controls (40.3% male, 
n=929; median age = 47, range 27–64 years) were included in the analysis 
(Figure 1). There were no significant differences between stroke respondents 
and non-respondents regarding sex, age, or stroke severity. The mean follow-up 
time from the index event was 5.7 years (SD = 2.9 years). Table 7 shows the 






























Men, n (%) 222 (63.1) 928 (40.3) 
Age at stroke (years), median (range)  48.8 (19.2–54.9)  
Age at follow-up (years), median (range) 54.0 (27–65) 47 (27–64) 
Body mass index, mean (SD) 28.9 (5.8) 26.6 (5.5) 
Time from stroke (years), mean (SD) 5.7 (2.9)  
Clinical signs at event, n (%)   
Aphasia 104 (29.5)  
Facial paresis  156 (44.3)  
Limb paresis 237 (67.3)  
Sensory loss 139 (39.5)  
Visual field defect 43 (12.2)  
Neglect 19 (5.4)  
Post-stroke infections 25 (7.1)  
Risk factors, n (%)   
Hypertension 191 (54.3) 545 (24.3) 
Coronary heart disease 20 (5.7)  
Myocardial infarction 17 (4.8) 27 (1.2) 
Heart failure 22 (6.3) 111 (5.0) 
Atrial fibrillation 32 (9.1)  
Diabetes 36 (10.2) 209 (9.3) 
Tobacco smoking 117 (33.2)  
High alcohol consumption 35 (9.9)  
Illicit drug use 1 (0.3) 288 (12.5) 
Stroke severity, n (%)   
Mild (NIHSS 0–6) 250 (71.2)  
Moderate (NIHSS 7–15) 69 (19.7)  
Severe (NIHSS ≥16) 32 (9.1)  
Stroke etiology, n (%)   
LAA 56 (15.9)  
CE 61 (17.3)  
SAO 35 (9.9)  
ODE 29 (8.2)  
UND 171 (48.6)  
Follow-up questionnaire, n (%)   
Depressive symptoms 237 (67.3) 222 (9.9) 
Not fully employed 266 (76.7)  
Tobacco smoking  78 (22.5)  
Recurrent stroke 40 (11.4)  
Recurrent myocardial infarction 31 (8.8)  




  Patients  (n=352) 
Controls 
(n=2304) 
Physical activity  
At least once a week 137 (40.2) 
Less than once a week 85 (24.9) 
Cannot exercise 119 (34.9) 
Modified Rankin score  
0 67 (19.1) 
1 49 (14.0) 
2 79 (22.5) 
3 58 (16.5) 
4 71 (20.2) 
5 27 (7.7) 
Note. CE, cardioembolism; LAA, large artery atherosclerosis; NIHSS, National Insti-
tutes of Health Stroke Scale; ODE, stroke of other determined etiology; SAO, small-
artery occlusion; SD, standard deviation; UND, stroke of undetermined etiology. 
 
 
The most frequently reported problems in the EQ-5D-3L among the patients 
were pain/discomfort (73.0%) and anxiety/depression (69.6%), followed by 
problems with usual activities (63.6%), mobility (63.1%), and self-care (41.8%; 
Table 8). Compared with the general population, the patients’ HRQOL was 
worse in all domains except for pain/discomfort, after adjusting for age, sex, 
and body mass index. The largest differences between patients and controls 
were in the physical domains (self-care, usual activities, and mobility) and, to a 
lesser extent, anxiety/depression. A total of 12.8% of patients and 27.3% of 
controls had no problems in any of the domains (p <0.001). The mean utility 
score among stroke survivors was significantly lower than that of the general 
population, after adjusting for age, sex, and body mass index (p <0.001; Table 
8). However, the subgroup of patients with excellent recovery (mRS 0–1) had a 
higher HRQOL in all of the EQ-5D-3L domains except for self-care, and after 
adjusting for age, sex, and body mass index compared with that of the general 
population. The mean utility score was also significantly higher in this group, 
compared with that of the general population (p >0.001; Table 9).  
In the multivariate analysis, coronary heart disease at the index event, higher 
follow-up duration, functional disability, depressive symptoms, recurrent 
stroke, and not being fully employed at follow-up were independently as-




Table 8. EQ-5D-3L dimensions and utility score in young stroke patients and controls.  





OR 95% CI p-value 
Mobility  222 (63.1%) 529 (23.4%) 4.16 3.22 to 5.38 < .001 
Self-care 147 (41.8%) 170 (7.4%) 6.83 5.14 to 9.08 < .001 
Usual activity 224 (63.6%) 429 (18.6%) 6.02 4.67 to 7.77 < .001 
Pain/discomfort 257 (73.0%) 1329 (60.0%) 1.30 1.00 to 1.69    .054 
Anxiety/depression 245 (69.6%) 1212 (52.6%) 1.96 1.53 to 2.52 < .001 
EQ-5D utility score, 
mean (SD) 
0.71 (0.28)      0.87 (0.14) -0.16 -0.18 to -0.14 < .001 
Note. CI, confidence interval; OR, odds ratio; SD, standard deviation. 
 
 
Table 9. EQ-5D-3L dimensions and utility score in young stroke patients with excellent 
functional outcome (modified Rankin score 0–1) and controls.  
 





OR 95% CI p-value 
Mobility  21 (18.1%) 529 (23.4%) 0.54 0.32 to 0.89 0.017 
Self-care 5 (4.3%) 170 (7.4%) 0.38 0.14 to 1.05 0.061 
Usual activity 16 (13.8%) 429 (18.6%) 0.55 0.31 to 0.97 0.038 
Pain/discomfort 53 (45.7%) 1382 (60.0%) 0.44 0.29 to 0.64 < 0.001  
Anxiety/depression 49 (42.2%) 1212 (52.6%) 0.65 0.44 to 0.95 0.026 
EQ-5D utility score, 
mean (SD) 
     0.91 (0.09)      0.87 (0.14) 0.07 0.03 to 0.10 < 0.001 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.1. Risk Factors and Etiology of Young Ischemic Stroke 
Patients (Paper I) 
This study comprised of a large, ethnically homogenous cohort of young patients 
with ischemic stroke. Since data on young ischemic stroke patients from Eastern 
Europe are scarce, it has provided information on stroke characteristics in this 
population. As overall life expectancy and working age increase globally, ex-
panding the upper age limit for defining young stroke patients seems appropriate; 
therefore, we chose 54 years as the cutoff age for our cohort.  
Results showed a high prevalence of vascular risk factors (83%), and the 
most common risk factors – hypertension, dyslipidemia, and smoking – are in 
line with the three largest studies of young ischemic stroke patients: the Hel-
sinki Young Stroke Registry (Putaala et al., 2009a), 15 Cities Young Stroke 
Study (Putaala et al., 2012a), and the SIFAP Study (von Sarnowski et al., 2013). 
However, our cohort had a higher prevalence of hypertension (53% vs. 36–
47%), atrial fibrillation (8% vs. 2–4%), coronary heart disease (9% vs. 4–6%), 
myocardial infarction (7% vs. 3–4%), and heart failure (7% vs. 1–5%). The 
higher frequency of well-documented risk factors in men and older age groups 
corroborates previous research (Putaala et al., 2009a; Renna et al., 2014; von 
Sarnowski et al., 2013). The pooled data from the 15 Cities Study, the FUTURE 
study, and the SIFAP Study (Maaijwee et al., 2014) showed a sharp rise in the 
prevalence of hypertension and dyslipidemia in those over the age of 35. In our 
study, the steep rise in the prevalence of hypertension and the combined pre-
valence of all well-documented risk factors began earlier in the late 20s (Figure 
3).  
The less well-documented risk factors in our cohort were characteristically 
more frequent in the younger age group and demonstrated sex disparity for 
migraine and heavy alcohol use (Putaala et al., 2009a; von Sarnowski et al., 
2013). The proportion of patients without any stroke risk factors has varied 
from 5–27% across studies (Goeggel Simonetti et al., 2015; Putaala et al., 
2009a; von Sarnowski et al., 2013) while in our data it comprised 11%.  
We also found that men’s predominance (67.3%) was the highest of previous 
reports (Goeggel Simonetti et al., 2015a; Putaala et al., 2009a; Putaala et al., 
2012a; Rolfs et al., 2013; Spengos & Vemmos, 2010) and men prevailed in all 
age groups. This is in contrast to several European studies, where women pre-
dominated among patients aged less than 35 years (Putaala et al., 2009a; Rolfs 
et al., 2013; Putaala et al., 2012a; Spengos & Vemmos, 2010). The Norwegian 
study, however, found men’s predominance in those under 30 years, like our 
study (Naess et al., 2011). We suggest that men’s predominance occured due to 
the early heavy burden of well-documented risk factors that outweighed 
women’s sex-specific risk factors (such as pregnancy, puerperium, use of oral 
contraceptives, and migraine with aura) that usually prevail in this age group. 
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Our study found that while stroke in the young patients was generally mild, 
it was more severe in men. Similarly, in the SIFAP (Rolfs et al., 2013) and 
Swiss Young Stroke Study (Goeggel Simonetti et al., 2015a) the majority of 
stroke cases were mild, with a median NIHSS score of 3, yet without diffe-
rences between the sexes. Since LAA and CE have shown to cause more severe 
symptoms than other TOAST subtypes (Tan et al., 2018), more severe stroke 
cases in men can probably be attributed to their increased proportion of LAA 
and CE compared with women. 
Our results regarding the overall proportion of LAA, CE, and SAO are 
similar to earlier studies (Barlas et al., 2013; Goeggel Simonetti et al., 2015a; 
Putaala et al., 2009a; Rolfs et al., 2013); however, the proportion of LAA in 
patients under age 35 is higher than previously reported (8 vs. 0–6%; Barlas et 
al., 2013; Nacu et al., 2016; Putaala et al., 2009a; Rolfs et al., 2013). This pre-
mature atherosclerosis could be attributed to the combination of both early 
clustering of atherogenic risk factors and genetic susceptibility. Major differen-
ces exist in the distribution of cardioembolic sources between our study and 
other European cohorts (Barlas et al., 2013; Putaala et al., 2009a). The rate of 
atrial fibrillation within the CE subtype has been reported to be 14–15%, while 
in our patients, it was 48%, which could be attributed to a higher cutoff age and 
an increased prevalence of hypertension, the greatest attributable risk of atrial 
fibrillation (Schnabel et al., 2015), in our cohort. The prevalence of ODE was 
8%, and within it, dissection accounted for 38% in our cohort, both of which 
were lower than in most series where the respective figures were approximately 
25% and 50% (Barlas et al., 2013; Goeggel Simonetti et al., 2015a; Nacu et al., 
2016; Putaala et al., 2009a; Rolfs et al., 2013). The differences in our findings 
are most likely due to methodological limitations of insufficient vascular 
imaging.  
Studies that have classified low-risk cardioembolic sources as CE and 
coagulopathies as ODE have reported roughly the same proportion of crypto-
genic stroke as ours (21 vs. 22–40%) (Barlas et al., 2013; Putaala et al., 2009a). 
As it is well recognized, the proportion of cryptogenic stroke decreased with 
age (Barlas et al., 2013; Putaala et al., 2009a; Rolfs et al., 2013) and – similarly 
to the 15 Cities study – was larger in women (Barlas et al., 2013). It has been 
hypothesized that temporary or unusual chronic risk factors, or genetic factors 
could be involved in cryptogenic stroke, as this is under investigation in a cur-
rent international multicenter prospective study (Putaala et al., 2017).  
Our cases represent more than 60% of young stroke cases in Estonia from 
the studied time-period, therefore the main study results, namely high pre-
valence of traditional vascular risk factors, high-risk CE causes and LAA in 
patients under 35 years, can be generalizable to the entire country. However, 
our study has several limitations, which are primarily related to its retrospective 
nature and hospital-based design. We suspect that behavioral risk factors, such 
as smoking, alcohol abuse, and body weight, were underreported in the medical 
records and their frequencies in this cohort and their impact on prognosis could 
be larger. Thirty percent of patients, mostly treated at the beginning of the 
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inclusion period, had incomplete diagnostic evaluation, which suggests that the 
rate of LAA and CE could be even higher. The low rate of ODE could also be 
attributed to insufficient work-up. In order to provide the most optimal secon-
dary prevention, the diagnostic work-up in young stroke patients should address 
a wide range of possible risk factors and causes. Our ongoing prospective 




6.2. Short- and Long-Term Mortality, Clinical Determinants 
and Causes of Death (Paper II) 
The short- and long-term mortality rates in our patient cohort were high. In 
studies conducted over the past two decades, the 30-day and 5-year mortality 
rates among young patients with ischemic stroke ranged from 0% to 3.6% 
(Greisenegger et al., 2011; Putaala et al., 2009; Renna et al., 2014; Rutten-
Jacobs et al., 2013), and from 5.8% to 11.0%, respectively (Greisenegger et al., 
2011; Naess et al., 2004; Putaala et al., 2009; Rutten-Jacobs et al., 2013; Varona 
et al., 2004). We report high short- and long-term mortality rate regardless of 
the upper age limit of either 44 or 54 years (3.1% and 4.5%; and 12.6% and 
16.8%, respectively). Nevertheless, the current long-term mortality rate is con-
siderably lower than the previously reported value of 25% in the Estonian 
population-based registry of patients under age 45 dating back to 1991–1993 
and 2001–2003 (Vibo et al., 2012). The cause of this trend is most likely multi-
factorial. On the one hand, the high vascular risk factor burden in our young 
patients (Paper I) might increase mortality, yet on the other hand, significant 
advances in organized stroke care (Kõrv & Vibo, 2013) could contribute to its 
decline. The management of stroke evolved during the study period in parallel 
with social welfare. The number of thrombolysed stroke cases have increased 
since 2003, and, in 2008, the Estonian Stroke Initiative was established to im-
prove stroke care, promote regional networks, and increase stroke knowledge 
among the general population and medical professionals (Kõrv & Vibo, 2013). 
The highest mortality among the TOAST subgroups was observed in CE 
stroke patients, consistent with previous findings from a Dutch study (Rutten-
Jacobs et al., 2013). However, in the Finnish and Swedish cohorts, the highest 
mortality was observed in the LAA group (Aarnio et al., 2014; Putaala et al., 
2009; Redfors et al., 2012). Our CE group had a remarkably large proportion of 
high-risk cardioembolic sources (91%, Paper I) compared to other studies (53–
60%; Barlas et al., 2013; Putaala et al., 2009a), which could potentially explain 
the high mortality in this category. One possible explanation for the increased 
mortality among men and older patients could be the greater prevalence of 
vascular risk factors in these patient groups (Paper I). 
To the best of our knowledge, this study is the first to report the deter-
minants of 30-day mortality among young patients with ischemic stroke. Severe 
stroke has been associated with early mortality in the general stroke population 
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(Nedeltchev et al., 2010), which was found to apply to young patients in the 
current study. The present study also showed that post-stroke infection pre-
dicted 30-day mortality, which has previously been associated with increased 
early mortality in young patients at the 3-month follow-up (Heikinheimo et al., 
2013).  
The long-term prognostic factors identified in the current study were post-
stroke infections, moderate stroke severity, and structural cardiac diseases. 
Patients with post-stroke infections during the first week also had significantly 
higher risks of death in a Finnish study (Heikinheimo et al., 2013). In the 
Finnish and our cohort, post-stroke infections increased the risk of long-term 
mortality by 2 to 3 times. The following mechanisms could explain the long-
term effects of immediate post-stroke infections: (1) prolonged hospital stay 
could delay rehabilitation, and (2) excessive inflammation could adversely 
affect stroke outcomes, possibly due to increased recurrent vascular attacks and 
delayed recovery. Hence, these findings highlight the need to prevent infections 
in young patients with stroke. Several validated prediction scores (Helmy et al., 
2016) have been used to identify patients at the highest risk of developing 
infections; such patients should be strictly monitored for the development of 
any infectious symptoms.  
Long-term mortality was also associated with moderate, rather than severe 
stroke, which affected the short-term mortality in our cohort. It is likely that 
patients’ death in cases of severe stroke occurred earlier during the acute phase. 
Our findings contradict the results of two earlier studies that reported that stroke 
severity did not significantly impact long-term mortality (Putaala et al., 2009; 
Rutten-Jacobs et al., 2013). Given that cardioembolism causes more severe 
stroke events than other stroke etiologies (Lin et al., 1996), the primary pre-
vention of cardiac embolism would have the greatest impact in reducing severe 
stroke events.   
There are no reports in the literature regarding 30-day death causes among 
young patients with ischemic stroke. In the general stroke population, deaths 
due to index stroke comprise 57% and those of all-vascular causes (ie cardiac 
and other vascular conditions in addition to stroke) account for 75% (Hartmann 
et al., 2001). In our young patient cohort, the respective proportions were 82% 
and 88%. These remarkable differences may be due to the lower number of 
comorbidities in young patients than in their older counterparts, which thus 
raises the proportion of stroke-related deaths in the young age group.  
In long-term deaths among young patients, vascular causes are attributable 
to 47%–57% (Greisenegger et al., 2011; Putaala et al., 2009; Rutten-Jacobs et 
al., 2013), which is in line with our results (55%). We found no statistical 
differences in the causes of death between sex and age groups. 
In conclusion, this study demonstrated high mortality in a carefully reviewed 
large set of consecutive young ischemic stroke patients. Accurate data on mor-
tality originated from two national registers – the Estonian Population Registry 
and the Estonian Causes of Death Registry – that are cross-linked to each other. 
As a limitation, we could not include all the TOAST subgroups in calculations 
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due to very small number of cases in some of them. Our results emphasize the 
need to better detect structural cardiac diseases by using highly sensitive 
imaging modalities and to treat them adequately. These measures will likely 
reduce the risk of CE strokes and cases with higher severity. Our study results 
also bring attention to the importance of preventing infections as means of 
reducing both short- and long-term mortality. Lastly, this analysis confirms the 
results from prior studies that follow-ups for young patients with ischemic 
stroke need to be long-lasting. 
 
 
6.3. Determinants of Long-Term Health-Related Quality of 
Life (Paper III) 
Our study of HRQOL in patients with ischemic stroke at a young age yielded 
four major findings: 1) stroke survivors’ HRQOL was lower than that in the 
general population; 2) patients with excellent recovery had higher HRQOL than 
their non-stroke counterparts; 3) HRQOL showed the most pronounced 
impairments in the physical domains; and 4) lower HRQOL was associated 
with stroke-specific, psychological, and socioeconomic factors.  
Stroke affects different aspects of HRQOL. A recent study by Katzan et al. 
reported that in the general ischemic stroke population, the most affected 
domains were physical function, satisfaction with social roles, and executive 
function (Katzan et al., 2018). In our cohort, the most pronounced differences 
relative to the non-stroke population were in the physical category. The psycho-
social domain was less affected, although it still showed a two-fold increase in 
young stroke patients compared with their non-stroke counterparts, and the 
difference in pain marginally missed significance. In a Norwegian population-
based study, the largest differences between young stroke patients and controls 
were related to physical functioning, but these were within one standard 
deviation (Naess et al., 2006). A Dutch study found that none of the EQ-5D 
subscale scores differed between young stroke patients and controls; however, 
this study included mainly stroke survivors with mild disability (de Bruijn et al., 
2015). Surprisingly, the subgroup with no or mild disability in the current study 
had a significantly higher HRQOL than the general population. Thus, it seems 
that an excellent functional outcome after stroke is associated with a general 
state of positivity, despite possible minor symptoms. Katzan et al. (2018a) 
found that ischemic stroke patients without disability or with mild disability had 
similar results to those reported in all Patient-Reported Outcomes Measurement 
Information System (PROMIS) health domains for the general population.  
The independent factors that have previously been associated with low 
HRQOL among young stroke survivors include depression, fatigue, unemploy-
ment (de Bruijn et al., 2015), higher mRS, motor dysfunction, and dysarthria 
(Kim et al., 2005). In addition to the identified factors of depressive symptoms, 
a mRS >0, and lack of full-time employment, our study identified other inde-
pendent factors, namely coronary heart disease during the index event, longer 
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follow-up duration, and recurrent stroke. Surprisingly, stroke etiology and seve-
rity were not associated with HRQOL in the multivariate model. Stroke recur-
rence was related to worse short-term HRQOL in the Acute Nondisabling 
Cerebrovascular Events (CHANCE) trial in the Asian population (Wang et al., 
2014), and in a UK population-based study, recurrent events decreased long-
term HRQOL in a group of patients with all types of stroke (Luengo-Fernandez 
et al., 2013). Our results revealed significantly lower utility scores with in-
creased follow-up time. A study from the Netherlands that included young 
patients with mild stroke reported that time from the event had no significant 
influence on HRQOL (de Bruijn et al., 2015). Data from longitudinal 
population-based studies with general stroke populations have also been incon-
sistent in this regard, as some showed no change (Luengo-Fernandez et al., 
2013) and others indicated a worsening of quality of life with time (Dhamoon et 
al., 2010).  
In terms of comorbidities, diabetes (Patel et al., 2007) has been detected as 
negatively affecting HRQOL after a stroke. Among young patients, no stroke-
specific risk factors have been previously examined. We included hypertension, 
atrial fibrillation, coronary heart disease, previous myocardial infarction, heart 
failure, diabetes, tobacco smoking, and high alcohol consumption at baseline in 
our analysis, with coronary heart disease being an independent predictor of 
poorer HRQOL. 
We intentionally did not include physical activity in the multivariate ana-
lysis, since a significant difference in the univariate analysis was detected 
between those with a moderate exercise level and those not able to engage in 
exercise at all, but not between moderate and low levels of physical activity. 
We concluded that this finding likely expressed functional disability and not the 
effects of exercise. An earlier meta-analysis on the effects of exercise on quality 
of life in stroke survivors found that exercise had a small effect on life quality at 
post-intervention, but no effect at follow-up after exercise was terminated 
(Chen & Rimmer, 2011). 
Our study revealed that HRQOL after ischemic stroke at a young age was 
most strongly associated with functional disability, depressive symptoms, and 
unemployment. It is noteworthy that all these factors can be modified and are 
easily assessed in everyday practice; thus, they should be targeted in the 
rehabilitation process.  
The main strength of our analysis is the large sample of real-life stroke 
patients exhibiting a full-range of severity, although the majority had expe-
rienced mild stroke, which is typical to this population (Goeggel Simonetti et 
al., 2015a; Rolfs et al., 2013) and the extensive population-based control group. 
The other strength is a relatively long follow-up period. This is especially 
applicable to this specific patient group, since their survival period tends to be 
longer, compared with that of the general stroke population. Regarding limita-
tions of the study, the response rate was 60% in spite of repeated reminders. 
However, sex, age, and stroke severity distributions between respondents and 
non-respondents were statistically similar. We did not collect data on socio-
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demographic factors (e.g., education, income and marital status), fatigue, and 
cognitive dysfunction, which could have affected the results.  
It is also, to our knowledge, the first study of its kind from Central and 
Eastern Europe. Unexplained variations exist in HRQOL across European 
general stroke populations (Ayis et al., 2015) and it is worth exploring it further 









1. The prevalence of traditional vascular risk factors among young Estonian 
ischemic stroke patients was high.  Hypertension, atrial fibrillation, coronary 
heart disease, myocardial infarction, and heart failure were more prevalent 
compared to similar data sets in other studies, which calls for more efficient 
primary prevention policy. Regarding etiology, premature atherosclerosis 
and high-risk cardioembolic sources were more common causes of ischemic 
stroke than in other European countries. Considerable proportion of patients 
were incompletely evaluated and, therefore, had potentially inappropriate 
secondary prevention. Standardized work-up schemes targeting a wide range 
of possible risk factors and etiology should be employed in young ischemic 
stroke patients for their most optimal secondary prevention.  
2. High short- and long-term mortality rates were associated with increased 
stroke severity, immediate post-stroke infections, and structural cardiac 
diseases. These findings emphasize the need for improved detection and 
treatment of structural cardiac diseases and implementation of validated 
scores for the prediction of infections.  
3. Ischemic stroke at a young age decreased the long-term HRQOL in most 
domains compared to the non-stroke controls. Since functional disability was 
strongly associated with poorer HRQOL and those with excellent functional 
outcomes had higher HRQOL, our study supports current rehabilitation prac-
tices where motor disabilities receive great attention. However, our analysis 
additionally highlights the importance of secondary prevention, treatment of 
depression, and career counseling as potential ways to increase HRQOL in 
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9. SUMMARY IN ESTONIAN 
Eesti noorte isheemilise insuldi patsientide riskitegurid, 
etioloogia ja hilistulemused  
Sissejuhatus 
Kõigist eluesmastest ajuinfarktidest 10–15% esineb alla 50-aastastel inimestel 
(Maaijwee jt, 2014). Nooreea insuldil on sageli sotsiaalselt laastav mõju, sest 
selles vanuses inimestel on tavaliselt perekondlike ja töökohustuste koorem 
kõige suurem. Kui üldiselt on isheemilisse insulti haigestumine viimastel küm-
nenditel vähenenud, siis noortel täiskasvanutel on see suurenenud (George jt, 
2011; Kissela jt, 2012; Ramirez jt, 2016; Rosengren jt, 2013; Tibæk jt, 2016). 
Noorte suurenenud haigestumust on seletatud muu hulgas vaskulaarsete riski-
tegurite kasvanud levimuse ning ajuinfarkti täpsema diagnostikaga, mis tuleneb 
magnetresonantstomograafiauuringu laialdasest kasutamisest (Putaala, 2016). 
Kuigi noorte ajuinfarktiga patsientide suremus on võrreldes vanemaealistega 
väiksem (Fonarow jt, 2010), on see siiski 4–15 korda suurem kui samaealistel 
tervetel inimestel (Aarnio jt, 2014; Giang jt, 2013; Marini jt, 1999; Rutten-
Jacobs, jt, 2013; Varona jt, 2004; Waje-Andreassen jt, 2007). Noorte patsientide 
suhteliselt parem elulemus tähendab, et nad elavad tekkinud puudega pikalt. 
Sellest tulenevalt tekib vajadus pöörata tähelepanu ka nende tervisega seotud 
elukvaliteedile, mille kohta on vähe andmeid.  
Tartus aastatel 1991–1993 ja 2001–2003 korraldatud rahvastikupõhistest 
uuringutest nähtub, et noorte haigestumus insulti oli sel ajal suurem kui Lääne- 
ja Põhja-Euroopa riikides. Nende uuringute alusel tõdeti, et Eesti mehed hai-
gestuvad insulti 2–7 ja naised kuni 5 aastat varem kui nende sookaaslased 
teistes Euroopa riikides (Kõrv jt, 1996; Vibo jt, 2007). Lisaks oli probleemiks 
alla 45-aastaste ajuinfarktiga patsientide suur suremus (5-aasta suremus 25%), 
mis püsis ajavahemikul 1991–2003 muutumatuna (Vibo jt, 2012). Eelnevat 
arvesse võttes püstitasime hüpoteesi, et noorea insuldi suur haigestumus ning 
suremus on tingitud eelkõige vaskulaarsete riskitegurite varajasest kuhjumisest. 
Seega vääris uurimist, missugused tegurid mõjutavad noorte ajuinfarktiga 
patsientide elulemust ning elukvaliteeti, et neil oleks selle info põhjal võimalik 




1. Analüüsida Eesti noorte isheemilise insuldi patsientide riskitegureid ja hai-
guse tekkepõhjuseid.  
2. Teha kindlaks noorelt haigestunute 30 päeva ja 5 aasta suremus, seda ennus-
tavad tegurid ja surmapõhjused. 
3. Hinnata noorelt haigestunute kohordis tervisega seotud elukvaliteedi hilis-
tulemusi ja tuvastada seda mõjutavad tegurid.  
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Uuritavad ja meetodid 
Uuringu valim moodustati järjestikustest isheemilise insuldi patsientidest, kes 
olid ravil Tartu Ülikooli Kliinikumis ja Põhja-Eesti Regionaalhaiglas ajavahe-
mikul 2003–2012 ning kelle vanus haigestumisel oli 18–54 aastat. Kõik haigus-
lood vaadati läbi ja valideeriti. Elulemuse andmed saadi rahvastikuregistrist 
ning surmapõhjuste kohta tehti päring surmapõhjuste registrisse 29.01.2019. a. 
seisuga. Tervisega seotud elukvaliteedi hindamiseks korraldati elus olevate pat-
sientide seas kirja teel ankeetküsitlus, mis sisaldas küsimusi 2012. a tervise-
käitumise uuringust, küsimusi korduvate vaskulaarsete atakkide ja ravimite 
tarvitamise kohta, jah-ei küsimusi modifitseeritud Rankini skoori määramiseks 
ja EuroQoL küsimustikku EQ-5D-3L (EuroQol-i mõõdik viie tervisliku kom-
ponendi hindamiseks 3-astmelisel skaalal). Selle uuringu võrdlusrühmaks oli 
Eesti täiskasvanud rahvastiku tervisekäitumise uuringu 2012. aasta valim.  
 Statistilisel analüüsil võrreldi kategoriseeritud tunnuseid hii-ruudu, Fisheri 
või Monte Carlo simulatsioonitestiga ning pidevaid tunnuseid Studenti t-testiga. 
Kumulatiivse suremuse hindamiseks rakendati Kaplani-Meieri meetodit. Ko-
handatud tulemite võrdlemisel kasutati logistilist või tobiti regressioonanalüüsi 




Esimese uuringu valimi suuruseks kujunes 741 patsienti, kellest 67,3% olid 
mehed. Patsientide keskmine vanus oli 46,9 ± 7,4 aastat, 30,1% olid vanuses 
18–44 aastat ning 69,9% vanuses 45–54 aastat. Vaskulaarsete riskitegurite levi-
mus oli 83,1%, neid esines rohkem meestel ja vanemas earühmas. Kõige suure-
ma levimusega riskitegurid olid hüpertensioon (52,9%), düslipideemia (45,5%) 
ja suitsetamine (34,7%). Tekkepõhjuste alarühmad jagunesid järgmiselt: suurte 
arterite ateroskleroos moodustas 17,1%, kardioemboolia 14,3%, väikeste vere-
soonte haigus 8,9%, teised täpsustatud põhjused 8,5%, krüptogeenne 20,5%, 
teadmata etioloogia ebapiisavate uuringute tõttu 30,4% ning kaks või enam 
põhjust oli 0,3%-l juhtudest. Kõige sagedasem kardioemboolia põhjus oli koda-
de virvendusarütmia (48%).  
 Teises uuringus oli keskmine jälgimise aeg 10,8 aastat. 30 päeva letaalsus oli 
4,5% (usaldusvahemik 3,0–6,0%), mitmemõõtmelises analüüsis osutusid seda 
ennustavateks teguriteks raske insult ning insuldijärgsel nädalal tekkinud infekt-
sioonid. Viie aasta kumulatiivne suremus oli 16,8% (95% usaldusvahemik 
14,1%–19,5%) ning see oli tunduvalt suurem meestel ja üle 44 aasta vanustel 
patsientidel. Etioloogilistest alarühmadest oli suurim suremus kardioembooliaga 
haigete rühmas. Surmapõhjused jagunesid järgmiselt: kardiaalsed põhjused 
moodustasid 36%, infektsioonid 21%, korduv insult 19%, kasvajad 14% ning 
traumad ja mürgistused 10%. Viie aasta suremust määravad tegurid olid insuldi-
järgsed infektsioonid, südame strukturaalsed häired (äge müokardiinfarkt, 
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kardiomüopaatia, südame klapihaigus, lahtine ovaalmulk koos kodade vahe-
seina aneurüsmiga ja südamekasvajad) ning keskmise raskusastmega insult.  
 Kolmandas uuringus vastas küsimustikule 352 patsienti, vastamismäär oli 
60,5% ja keskmine jälgimisaeg 5,7 aastat. Vastanutest oli mehi 63,1% ja pat-
sientide mediaanvanus oli 54 aastat (vahemik 27–65 aastat). Võrdlusrühmas oli 
2304 inimest. Patsientide tervisega seotud elukvaliteeti iseloomustav väärtus-
skoor oli võrreldes üldrahvastikuga väiksem (vastavalt 0,71 ja 0,87, p < 0,001), 
kõige suuremad erinevused esinesid seoses füüsilise tervisega (liikumine, enese 
eest hoolitsemine, igapäevased tegevused). Samas oli minimaalse funktsio-
naalse puudega patsientide (Rankini modifitseeritud skoor 0–1) elukvaliteet 
võrdlusrühmast parem (vastavad väärtusskoorid oli 0,91 ja 0,87, p < 0,001). 
Mitmemõõtmelises analüüsis osutusid halba elukvaliteeti ennustavateks teguri-
teks koronaararterite haigus insulti haigestumisel, pikem jälgimisaeg, raskem 
funktsionaalne puue, depressioonisümptomid, korduv insult ja võimetus töötada 




1. Vaskulaarsete riskitegurite levimus Eesti noortel isheemilise insuldi patsien-
tidel on suur, mis viitab asjaolule, et vajalik on tõhusam primaarne prevent-
sioon. Märkimisväärsele osale patsientidest ei olnud tehtud kõiki vajalikke 
diagnostilisi uuringud, seega on võimalik, et ka nende sekundaarne ennetus 
jäi ebapiisavaks. Isheemilise insuldiga noorte patsientide käsitlus peaks 
olema standardiseeritud ning suunatud kõigi potentsiaalsete riskitegurite ja 
põhjuste tuvastamisele, et võimaldada parimat sekundaarset ennetust. 
2. Suremusrisk on seotud raskema insuldi, vahetute insuldijärgsete infektsioo-
nide ja südame strukturaalsete häiretega. Uuringu tulemused näitavad, et 
noorte isheemilise insuldiga patsientide seas on vaja rakendada tõhusamaid 
ennetusstrateegiaid (nt varakult diagnoosida südamehaigusi ning juurutada 
infektsioonide ennustamiseks ja ennetamiseks valideeritud skaalad).  
3. Isheemilise insuldi tõttu halveneb tervisega seotud elukvaliteet. Kuna funkt-
sionaalne puue määrab elukvaliteeti, on õigustatud liikumisfunktsioone 
taastava ravi seadmine esikohale. Samas vajavad noortel patsientidel tähele-
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10.  APPENDICES 
Appendix A. Calculation of Risk of Paradoxical Embolism Study (RoPE) score 
(adapted from Kent et al., 2013) 
 
Characteristic Points 
No history of hypertension 1 
No history of diabetes 1 
No history of stroke or TIA 1 
Nonsmoker 1 
Cortical infarct on imaging 1 









Appendix B. Trial of Org 10172 in Acute Stroke Treatment Classification (TOAST) of 
ischemic stroke subtypes (adapted from Adams et al., 1993) 
 
Large artery atherosclerosis 
Cardioembolism 
1) Sources with high risk  
a. left atrial and left ventricular thrombus 
b. atrial fibrillation  
c. sick sinus syndrome  
d. bioprosthetic and mechanical heart valve  
e. recent myocardial infarction, etc. 
2) Sources with low or uncertain risk 
a. mitral annular calcification 
b. patent foramen ovale 
c. atrial septal aneurysm 
d. patent foramen ovale with atrial septal aneurysm 
Small artery occlusion 
Stroke of other determined etiology 
Stroke of undetermined etiology 
1)    No obvious cause despite extensive diagnostic evaluation (i.e., cryptogenic 
stroke)  
2)    Two or more concurrent causes   






Appendix C. Calculation of National Institutes of Health Stoke Scale (NIHSS) score 
(adapted from Powers et al., 2018)  
 
Tested Title Responses and Scores
1A  Level of consciousness 0—Alert 
 1—Drowsy  
 2—Obtunded  
 3—Coma/unresponsive  
1B  Orientation questions    0—Answers 2 questions correctly  
 1—Answers 1 question correctly  
 2—Answers neither correctly  
1C  Response to commands 0—Performs 2 tasks correctly  
 1—Performs 1 task correctly  
 2—Performs neither  
2  Gaze  0—Normal horizontal movements  
 1—Partial gaze palsy  
 2—Complete gaze palsy  
3  Visual elds  0—No visual field defect  
 1—Partial hemianopia  
 2—Complete hemianopia  
 3—Bilateral hemianopia  
4  Facial movement  0—Normal  
 1—Minor facial weakness  
 2—Moderate facial weakness  
 3—Complete unilateral palsy  
5  Motor function (arm)  0—No drift  
a. Left  1—Drift before 10 seconds  
b. Right  2—Falls before 10 seconds  
 3—No effort against gravity  
 4—No movement  
6  Motor function (leg)  0—No drift  
a. Left  1—Drift before 5 seconds  
b. Right  2—Falls before 5 seconds  
 3—No effort against gravity  
 4—No movement  
7  Limb ataxia  0—No ataxia  
 1—Ataxia in 1 limb  
 2—Ataxia in 2 limbs  
8  Sensory  0—No sensory loss  
 1—Mild sensory loss  
 2—Severe sensory loss  
9  Language  0—Normal  
 1—Mild aphasia  
 2—Severe aphasia  
 3—Mute or global aphasia  
10  Articulation  0—Normal  
 1—Mild dysarthria  
 2—Severe dysarthria  
11  Extinction or inattention  0—Absent  
 1—Mild loss   





Appendix D.  Modified Rankin scale (mRS; adapted from van Swieten et al, 1988) 
 
Score Description 
0 No symptoms at all 
1 No significant disability despite symptoms 
2 Unable to carry out all previous activities, but able to look after 
own affairs without help 
3 Requiring some help, able to walk without assistance 
4 Unable to walk without assistance and unable to attend to own 
bodily needs without assistance 






Appendix E. Three-level version of EQ-5D (EQ-5D-3L; adapted from EuroQol 
Research Foundation, n.d.) 
 
Mobility 
 I have no problems in walking about  
 I have some problems in walking about  
 I am confined to bed 
Self-care 
 I have no problems with self-care 
 I have some problems washing or dressing myself 
 I am unable to wash or dress myself 
Usual activities (e.g. work, study, housework, family or leisure activities) 
 I have no problems with performing my usual activities 
 I have some problems with performing my usual activities  
 I am unable to perform my usual activities 
Pain/discomfort 
 I have no pain or discomfort 
 I have moderate pain or discomfort  
 I have extreme pain or discomfort 
Anxiety/depression 
 I am not anxious or depressed 
 I am moderately anxious or depressed 
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